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Abstract

Tumor necrosis factor alpha (TNF-α) is a proinflammatory cytokine with
homeostatic and pathological roles in the central nervous system. The main objective
of this dissertation is to study the impact of presence and absence of TNF-α on kainic
acid (KA)-induced neurotoxicity at several time points (0.5 and 4 hr as well as 1, 3,
5, 15 and 30 days) to find out the possible mechanisms underlying its effects. KA (40
mg/kg) was given intranasally to TNF-α knockout (Ko) mice and C57BL/6 wild-type
(Wt) mice. Seizure severity was scored and behavioral tests including Elevated PlusMaze (EPM), open-field, and Y-maze were performed. The hippocampal levels of
cytokines (IL-1β, IL-6, IL-12, IL-10), Insulin-like growth factor-I (IGF-I), and nerve
growth factor (NGF) were assessed. Hippocampal oxidative stress markers including
malondialdehyde, nitric oxide, glutathione (GSH), catalase and superoxide dismutase
(SOD) were evaluated.

Immunohistochemical methods were used to assess

neurodegeneration and glial activation.

Compared with Wt-mice, TNF-α Ko mice were more susceptible to KAinduced neurotoxicity by showing rapid onset (P<0.001) and severe seizures
(P<0.01). In EPM, TNF-α Ko mice showed changed risk assessment performance
(P<0.01) especially at 30 days post KA. In open field test, TNF-α Ko mice showed
significant hyperactivity at 3 and 30 days post KA treatment. In the Y-maze at 30
days post KA, TNF-α Ko mice showed significantly lower percent alternation
compared

to

the

respective

KA-treated

Wt-mice.

Increased

levels

of

proinflammatory cytokines (IL-1β, IL-6 and IL-12) as well as decreased levels of
anti-inflammatory cytokines (IL-10) were observed in both strains following KA-

viii
treatment. KA-treated TNF-α Ko mice showed more severe oxidative stress
(P<0.01), lower IGF-I levels (P<0.05), and higher levels of β-NGF (P<0.05)
compared to Wt-mice. Hippocampal GSH levels were significantly elevated in Wtmice but not in TNF-α Ko mice, while, catalase and SOD activity were elevated
(P<0.001) in TNF-α Ko mice. Hippocampal microglial activation and astrogliosis
were significantly enhanced and persisted up to 30 days in TNF-α Ko mice compared
with Wt-mice. Moreover, significant hippocampal CA3 neurodegeneration was
observed 3 days post KA-treatment in both TNF-α Ko and Wt-mice compared to
controls. The neurodegeneration was progressive and more significant (P<0.01) in
TNF-α Ko mice compared with Wt-mice. Additionally, KA-treatment significantly
up-regulated NFκB expression at 5 days post KA in TNF-α Ko mice. Taken together,
our findings showed that deficiency of TNF-α worsens KA-induced neurotoxicity.
These results highlighted the protective effects of TNF-α in KA-induced
neurotoxicity and suggested that these neuroprotective effects may be through the
regulation of microglial activation, induction of antioxidant defensive mechanisms
and regulation of the NFκB signaling pathway.

Keywords: Tumor necrosis factor alpha (TNF-α), Neurodegeneration, Kainic acid,
Neuroinflammation, Microglia, Growth factors, Oxidative stress, NFκB.
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)Title and Abstract (in Arabic

دور تي إن إف ألفا ) (TNF-αفي موت الخاليا العصبية في الحصين
الملخص
يعتبر ( )TNF-αمن البروتينات والسيتوكينات المحفزة لاللتهاب وله العديد من الوظائف التنظيمية
باإلضافة إلى بعض التأثيرات المسببة لألمراض في الجهاز العصبي المركزي  .ويعد الهدف الرئيسي من هذه
األطروحة هو دراسة تأثير وجود بروتين ( )TNF-αعلى موت الخاليا العصبية المستحدث باستخدام حمض
الكاينيك ( )Kainic acidودراسة تأثيراته على فترات زمنية مختلفة بهدف معرفة بعض اآلليات المحتملة
لتأثيراته.

ولتحقيق هذه األهداف  ،قمنا باستخدام نوعين من الفئران أحدهما يحمل الجين الخاص ببروتين
( )TNF-αوينتجه ويسمى فئران النوع البري ( )Wtواآلخر ال يحمل الجين الخاص ببروتين ( )TNF-αومن
ثم ال ينتجه ويسمى فئران ( . )TNF- Koوقسمت الفئران إلى مجموعات تمثل الفترات الزمنية المختلفة
للدراسة وأعطيت مادة حمض الكاينيك بجرعة ( 04ملغم  /كغم من وزن الجسم) عن طريق األنف  ،بينما تم
إعطاء مجموعات التحكم ماءا مقطرا .وبعد االنتهاء من الجرعة كاملة قمنا بتسجيل شدة النوبات الصرعية
( )Seizuresالتي تمر بها الفئران عقب التعرض لحمض الكاينيك  .كما أجرينا بعض االختبارات السلوكية
للفئران ( . )Elevated plus maze, Open Field and Y-mazeإضافة لما سبق فقد قمنا باستخراج
منطقة الحصين ( )Hippocampusمن أدمغة الفئران وقسنا فيها مستويات السيتوكينات المختلفة ( IL-6,
 ، )IL-12, IL-1β, IL-10وكذلك مستويات عامل النمو المشابه لألنسولين ( ، )IGF-Iوعامل نمو
األعصاب ( . )NGFكما تم قياس معدالت العديد من معامالت اإلجهاد التأكسدي بما في ذلك مادة
المالوندايلديهيد ( )MDAوأكسيد النيتريك و الجلوتاثيون ( )GSHوإنزيم الكاتالز ( )Catalaseوإنزيم
()Superoxide dismutase SOD

في الحصين ( . )Hippocampusواستخدمت الطرق المناعية

لصباغة أنسجة المخ ( )Immunohistochemical methodsمن أجل تقييم موت الخاليا العصبية ومدى
نشاط الخاليا الغير عصبية في المخ (. )Neuroglia

x
ولقد أظهرت النتائج أن فئران ( )TNF- Koأكثر عرضة وحساسية تجاه اإلصابة العصبية
الناجمة عن حمض الكاينيك مقارنة مع فئران النوع البري ( . )Wtوظهر ذلك جليا في سرعة ظهور النوبات
الصرعية ( )Seizuresوزيادة شدتها  .وفي اختبارات السلوك ظهر تغير ملحوظ في قدرة فئران ( TNF-
 )Koعلى تقدير الخطر خصوصا بعد ثالثين يوما من التعرض لحمض الكاينيك باإلضافة إلى زيادة واضحة
في النشاط الحركي لها مع تدهور ملحوظ في كفاءة الذاكرة القصيرة لهذه الفئران  .وقد لوحظت زيادة
مستويات السيتوكينات المحفزة لاللتهاب ( )IL-6, IL-12, IL-1βوكذلك انخفاض مستويات السيتوكينات
المضادة لاللتهاب ( )IL-10في نوعي الفئران بعد التعرض لحمض الكاينيك  .واتضح أن مستويات بروتين
( )IGF-Iكانت أقل بينما مستويات بروتين ( )NGFكانت أعلى في فئران ( )TNF- Koمقارنة بفئران
النوع البري ( )Wtبعد تعرضها لحمض الكاينيك .

وقد الحظنا أيضا أن اإلجهاد التأكسدي كان أكثر شدة في فئران ( . )TNF- Koأما بالنسبة
للدفاعات المختلفة للجسم في مواجهة اإلجهاد التأكسدي  ،فقد ارتفعت مستويات الجلوتاثيون ( )GSHفقط في
فئران النوع البري ( )Wtوليس في فئران ( . )TNF- Koوارتفع نشاط إنزيمي ()Catalase & SOD
بشكل أوضح في فئران ( )TNF- Koكآلية دفاعية ضد زيادة اإلجهاد التأكسدي  .كما تبين أن مستويات
بروتين ( )NFBقد ارتفعت في فئران ( )TNF- Koبعد  5أيام من التعرض لحمض الكاينيك .

أما بالنسبة للخاليا غير العصبية ( ، )Microglia & Astrocytesفقد لوحظ ازدياد نشاطها
وفاعليتها خالل مدة الدراسة واستمرت مرحلة نشاطها لمدة شهر في فئران ( )TNF- Koمقارنة بفئران
النوع البري ( . )Wtإضافة إلى ذلك فقد بدا موت الخاليا العصبية جليا في منطقة ( )CA3من الحصين بعد
ثالثة أيام من التعرض لحمض الكاينيك في نوعي الفئران المستخدمة  .ولوحظ أن موت الخاليا العصبية
تدريجي ويزداد بمرور الوقت وهو أكثر شدة في فئران ( )TNF- Koمقارنة بفئران النوع البري (. )Wt

وإجماال  ،فقد أظهرت هذه الدراسة أن نقص ( )TNF-يفاقم من موت الخاليا العصبية المستحدث
باستخدام حمض الكاينيك  .وتقدم نتائج هذه الدراسة إسهاما في إبراز التأثيرات الواقية التي يقلل بها بروتين
( )TNF-موت الخاليا العصبية الذي يسببه حمض الكاينيك  .ولعل من اآلليات المحتملة لللتأثيرات الواقية

xi
لبروتين ( )TNF-قدرته على تنظيم نشاط الخاليا غير العصبية ( )Microgliaو تحفيز اآلليات الدفاعية
ضد اإلجهاد التأكسدي باإلضافة إلى ظبط وتنظيم مستويات بروتين (.)NFB

كلمات البحث المساعدة  :بروتين ( ، )TNF-αموت الخاليا العصبية  ،حمض الكايينيك  ،االلتهاب العصبي ،
الخاليا غير العصبية ( ، )Microgliaعوامل النمو  ،اإلجهاد التأكسدي  ،بروتين (. )NFB
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Chapter 1: Introduction
1.1

Neurodegeneration

1.1.1

Definition
Neurodegeneration is the umbrella term for the progressive loss of structure

or function of neurons, including death of neurons (Rubinsztein, 2006). A
neurodegenerative disease is an irreversible deterioration in the intellectual and
cognitive functions as a result of gradual and progressive loss of structure and/or
function of neurons (Brown et al., 2005). Neurodegenerative diseases represent a
wide group of central nervous system (CNS) diseases with different clinical and
pathological features affecting specific neurons in the brain, mostly due to unknown
causes, and progress in an unexpected manner. The most common neurodegenerative
diseases are Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington disease
(HD), and amyotrophic lateral sclerosis (ALS) (Przedborski et al., 2003).

1.1.2

Factors Contributing to Neurodegeneration
In general, the major risk factor for developing neurodegenerative diseases is

old age; however they can also affect young adults (Forman et al., 2004). As a result
of the huge improvements in health care and medical research, the population lives
longer, and an increasing number of elderly people will suffer from
neurodegenerative diseases. The exact cause of neurodegenerative diseases is still
debatable. Although the study of inherited familial cases has provided insight into the
genetic factors (Shastry, 2003), many studies reported that an interaction between
aging, environmental factors, and genetic predisposition contributes to the
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development of neurodegenerative diseases (Campbell, 2004). Multiple components
are linked to the pathogenesis of neurodegenerative diseases including protein
aggregation (Rubinsztein, 2006), mitochondrial dysfunction and oxidative stress (Lin
and Beal, 2006), diet components and neurotoxins (Brown et al., 2005), vascular
disorders, excitotoxicity (Salinska et al., 2005), and inflammation (Wyss-Coray and
Mucke, 2002).

1.1.3

Pathogenesis of Neurodegenerative Diseases
The pathogenesis and the mechanisms underlying neurodegeneration are still

not completely defined. The shared characteristic of all neurodegenerative disorders
is the selective and progressive loss of neurons in specific brain structures (Golde,
2009). Based on the study of patients with genetic forms of common and uncommon
neurodegenerative diseases it can be inferred that the majority of these diseases
feature a fairly long disease free period in which no pathological or clinical changes
are noted. Subsequently, there is a phase that may last for years or even decades
where the initiating pathology is detectable, but the patient remains symptom free.
During this phase, additional pathological changes occur in the brain, including
neuronal loss, atrophy, and synaptic dysfunction (Byrne et al., 2011). Thus, when
symptoms become apparent there is typically extensive damage to either vulnerable
brain regions in diseases that are characterized by more focal dysfunction or
widespread damage to multiple brain regions (Byrne et al., 2011; Golde, 2009).
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1.1.4

Neurodegeneration and Therapeutics
The majority of neurodegenerative diseases are difficult to diagnose

accurately, and a clinical diagnosis is usually made through a process of elimination
(Emard et al., 1995; Shaw et al., 2007). At present, the pharmacological therapy of
neurodegenerative diseases is limited mostly to symptomatic treatments that do not
alter the course of the underlying disease and have many side effects (Przedborski et
al., 2003). Symptomatic treatment for PD, where the neurochemical defect produced
by the disease is well defined, is relatively successful, and a number of effective
agents are available. The available treatments for AD, HD, and ALS are much more
limited in effectiveness (Shaw et al., 2007). In order to find effective treatments, we
should

understand

the

pathogenesis

and

the

mechanisms

underlying

neurodegeneration, which are still not completely defined till now. An important goal
of much current research in the pharmacology of neurodegenerative disorders is the
identification of drugs that can slow the underlying degenerative process.

1.1.5

Effect of Neurodegeneration on Families and Society
Each year over 10 million people suffer from neurodegenerative diseases,

with an expected 20% increase over the next decade. This increase in the aging
population will exaggerate the level of emotional, physical, and financial burdens on
patients, caregivers, and society (Atkinson, 2010; The Lancet, 2013).

1.1.6

Experimental Models of Neurodegeneration
Experimental animal models are necessary to understand the disease etiology,

pathophysiology, compensatory mechanisms and progression, to establish new
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therapeutic strategies, and to extend the pharmacological approach towards a more
effective treatment for patients with neurodegenerative diseases.

Several

experimental

models

have

been

established

to

study

neurodegeneration. In vitro models involved the use of neonatal neuron cell cultures
or adult brain slice cultures (Legradi et al., 2011). In vivo models involved surgical
brain lesions, administration of neurotoxins (MPTP, Kainic acid, Domoic acid), or
genetic manipulation (Butler et al., 2003; Kirik and Bjorklund, 2003; Waerzeggers et
al., 2010). Most of these models result in neurodegeneration in targeted regions of
the brain that will mimic what happened in various neurodegenerative disorders.

Unfortunately, no single animal model is entirely useful in reproducing the
complete spectrum of pathological changes observed after neurodegeneration and
further research is necessary to fully reveal the acute and chronic changes that occur
after neurodegeneration. Although it is difficult to create a comprehensive animal
model for neurodegenerative diseases, the current models are still useful to give us
different parts from the whole picture, and hopefully when these parts are put
together we could know more about the reality of the neurodegeneration.

1.2

Neurodegeneration and Inflammation
Inflammation in the brain is termed neuroinflammation. It is a fundamental

response generated to protect the CNS; however, uncontrolled or prolonged
neuroinflammation is potentially harmful and can result in cellular damage. This is
particularly relevant to neurodegenerative diseases, which are typified by evidence of
microglial activation and neuroinflammation (Doty et al., 2015; Frank-Cannon et al.,
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2009). Previously, inflammation was viewed as only a passive response to neuronal
damage. However, increasing reports demonstrate that inflammation is capable of
actively causing neuronal death and damage (Streit et al., 2004; Sundaram and
Gowtham, 2012). Thus, while the triggers of various neurodegenerative diseases are
diverse, inflammation may be a basic mechanism driving the progressive nature of
multiple neurodegenerative diseases. Several cell types have been listed as
contributors to inflammation-mediated neurodegeneration, but microglia are
considered the critical component (Block and Hong, 2005). Since neurodegeneration
involves a chronic inflammatory process. the inflammatory molecules may be
crucially

implicated

at

various

stages

in

the

pathological

cascade

of

neurodegenerative diseases (Glass et al., 2010). Thus, anti-inflammatory treatment
may slow down the process of neurodegeneration. Consequently, it is important to
focus on the role of inflammatory mediators in the pathology of neurodegeneration.

1.2.1

Sources of Inflammatory Mediators in the CNS
The brain is considered as an immune privileged organ, due to its

compartmentalization and separation from the peripheral blood system by the blood
brain barrier (BBB). The impermeability of the BBB prevents the entrance of
immunoglobulins and the invasion of leukocytes from blood. However, many
immunocompetent molecules, such as various cytokines and chemokines and their
receptors, have been identified within the CNS (Nakamura, 2002). These findings
confirm that there are resident cells in the CNS that work as immune cells and
produce

these

molecules

(Nakamura,

2002;

Prinz

et

al.,

2014).

Most

neurodegenerative diseases are characterized by both local inflammation from
resident cell types in the brain and by the infiltration of leucocytes from the
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periphery (Kurkowska-Jastrzebska et al., 1999). While infiltrating peripheral immune
cells can be significantly toxic to neurons (Wu and Proia, 2004), leukocyte
infiltration is not always associated with neurotoxicity (Trifilo and Lane, 2003). This
indicates a critical role for the local glial cells (astroglia and microglia) in the
inflammatory response associated with neurodegeneration.

1.2.2

Glial cells
In the CNS, there are three kinds of glial cell other than neurons: astrocytes,

oligodendrocytes, and microglia. These cells are surrounded by capillary endothelial
cells and ependymal cells. The endothelial cells form the BBB that isolates central
cells from peripheral tissues by maintaining highly stable conditions within the CNS
(Nakamura, 2002).

1.2.2.1 Astroglia
In the normal brain, astroglia play essential roles in providing glia-neuron
contact, maintaining ionic homeostasis, buffering excess neurotransmitters, secreting
neurotrophic factors, and serving as a critical component of the blood–brain barrier
(Aloisi, 1999; Fiacco et al., 2009). Although the pro-inflammatory function of
astroglia is not as prominent as that of microglia (Streit et al., 1999), astroglia
become activated in response to immunologic challenges or brain injuries (Colangelo
et al., 2014). Astroglia also produce a host of trophic factors (Lindsay, 1994), which
are crucial for the survival of neurons. However, activated astroglia become
hypertrophic, exhibit increased production of glial fibrillary acidic protein (GFAP),
and form glial scars, which prevent axonal regeneration (Fiacco et al., 2009).
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1.2.2.2 Microglia
In all tissues of the body, there is a population of resident macrophages.
These cells form a first line of defense against tissue injury or infection, and rapidly
respond to alterations in tissue homeostasis. Microglia are the major resident immune
cells in the CNS parenchyma, where they constantly survey the microenvironment
and produce factors that influence surrounding astrocytes and neurons (Glass et al.,
2010). They were originally described by del Rio-Hortega (1932) as a unique cell
type differing in morphology from other glia and neurons, comprising approximately
12% of the brain. They are responsible for the innate immune response in the brain.
They perform general maintenance and clean cellular debris (Beyer et al., 2000).
Additionally, microglia have active roles in late embryonic brain development and
early postnatal brain maturation, where microglia enforce the programmed
elimination of neural cells (Barron, 1995; Prinz et al., 2014).

1.2.3

Dynamics of Microglial Cells
Microglial cells have been classically described to exist in two states, resting

and activated (Morgan et al., 2004). However, this binary definition has been revised
to make way for more complex ideas. Microglia, in the healthy CNS, are not truly
“resting”, but engaged in environmental surveillance, constantly sampling areas
around them to maintain homeostasis (Nimmerjahn et al., 2005). Once microglia
encounter changes in homeostasis, infection or injury, they enter an “activated” state
in order to regulate CNS innate immunity and initiate appropriate responses, such as
inflammation (Perry et al., 1995). It is now recognized that activated microglia can
exist broadly in two different states (Colton, 2009). The first is classical activation,
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which is typified by the production of inflammatory cytokines and reactive oxygen
species, while the second is a state of alternative activation, in which microglia take
on an anti-inflammatory phenotype involved in wound repair and debris clearance
(Cherry et al., 2014; Gordon, 2003).

1.2.3.1

M1 and M2 Microglia
Once microglial cells are activated, they up-regulate a variety of surface

immune receptors, such as toll-like receptors, the major histocompatibility complex,
and complement receptors (Ransohoff and Brown, 2012). They also undergo
dramatic morphological changes from resting ramified cells to activated amoeboid
microglia (Kreutzberg, 1996). Besides morphological changes and surface molecule
upregulation, activated microglial cells secrete a host of soluble factors. Some of
these factors, such as the glia-derived neurotrophic factor, are potentially beneficial
to the survival of neurons (Aloisi, 1999). The majority of factors produced by
activated microglia, however, are proinflammatory. These include the cytokines
TNF-α, IL-6, IL-1β, interferon-γ (IFN-γ) and several chemokines (Boche et al., 2013;
Lee et al., 1993), free radicals such as nitric oxide (NO) (Liu et al., 2002), and
superoxide (Colton and Gilbert, 1987), fatty acid metabolites such as eicosanoids,
and quinolinic acid (Liu and Hong, 2003). The cytokine production is essential for
the polarization of microglia into a classically activated, “M1”, state (Mills et al.,
2000). IFN-γ produced from Th1 cells was found to be instrumental in polarizing
macrophages to M1 (Nathan et al., 1983). Microglia and astrocytes have also been
observed to produce IFN-γ (Kawanokuchi et al., 2006), demonstrating that microglia
can control their own polarization through autocrine and paracrine means. Normally,
it is supposed that the classical activation of microglia is protective, self-limiting and
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is under strict control; resolving once infection has been eradicated or the tissue
damage has been repaired (Glass et al., 2010). However, unregulated, long-term, or
chronic inflammation can lead to tissue destruction (Perry and Teeling, 2013).

Alternatively activated macrophages, “M2 microglia”, express cytokines and
receptors that are implicated in inhibiting inflammation and restoring homeostasis.
This includes production of IL-10 to downregulate inflammatory cells, extracellular
matrix protecting proteins like YM1, polyamines for wound repair, neuroprotective
factors like IGF-I or brain derived neurotrophic factor and higher levels of receptors
associated with phagocytosis, such as scavenger receptors (Martinez et al., 2009).
Just as the Th1 cytokine IFN-γ has been associated with induction of
proinflammatory M1 macrophages, the Th2 cytokine IL-4 has been associated with
M2, or alternative activation (Stein et al., 1992). Interestingly, it appears that when
there is a lack of M2 cell differentiation in the CNS, problems can arise because of
lower levels of neuroprotective factors like IGF-I or brain derived neurotrophic
factor, which microglia produce (Amor et al., 2010). Indeed, many investigators are
starting to recognize the importance of M1/M2 dynamics in diseases characterized by
chronic neuroinflammation.

1.2.3.2

Activated Microglia May Be Protective or Toxic
A lot of controversy exists regarding whether microglia are neuroprotective

or neurotoxic when activated. In addition to producing cytotoxic factors such as
superoxide, nitric oxide, and TNF- in response to immunological stimuli, microglia
are also reported to increase neuronal survival through the release of trophic and antiinflammatory factors. Thus, it is likely that microglia can serve both functions,
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depending on several factors ranging from the progression of the disease state to the
type of stimulus. Although some inflammatory stimuli induce beneficial effects (e.g.,
phagocytosis of debris and apoptotic cells), and inflammation is linked to tissue
repair processes, over-activation of microglia and consequent uncontrolled
inflammation may result in production of neurotoxic factors that amplify underlying
disease states (Block and Hong, 2005; Glass et al., 2010).

1.2.4

Microglial Activation in CNS Diseases
In the past, it was a general understanding that microglia are consequently

activated after neuronal damage to phagocytose the damaged neurons, after which
the postneuronal space is occupied by the proliferation of reactive astrocytes (gliosis
or astrocyte scarring). However, Morioka and coworkers observed in (1991) that the
microglial activation began before the neuronal degeneration in an animal model of
transient brain ischemia. Since then, the possibility has been examined in various
experimental systems that “microglial activation” may be a cause of neuronal
degeneration rather than a consequence of it.

In vitro, microglial cells represent the large majority of proliferating cells in
slice cultures after exposure to α-amino-3-hydroxy-5-methyl-4-isoxazole propionic
acid (AMPA) or to N-methyl-D-aspartate (NMDA) (Dehghani et al., 2004). An
increase in microglia reactivity and proliferation close to degenerating neurons was
also observed in the brain of kainate-treated rats (Tooyama et al., 2002) and in
models of cerebral ischemia (Dempsey et al., 2003). These cells were localized
preferentially close to the damaged and dying neurons.
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Studies using cell culture and animal models have demonstrated that
excessive quantities of individual factors produced by activated microglia can be
deleterious to neurons (Chao et al., 1992; McGuire et al., 2001). Furthermore,
individual factors often work together to induce neurodegeneration. Xie and
coworkers in (2002) showed that peroxynitrite, a product of superoxide and NO, is a
major mediator of neurotoxicity induced by lipopolysaccharide (LPS) or β-amyloid
peptide (Aβ 1-42).

The involvement of microglial activation in the pathogenesis of several
neurodegenerative diseases was initially postulated based on the postmortem analysis
of the brains of patients with AD and PD. Reactive microglia were found to
colocalize with neuritic plaques in the cortical region of AD brains (Rogers et al.,
1988). In PD brains, large numbers of reactive microglia were found in the substantia
nigra (McGeer et al., 1988). In addition to AD and PD, results from both in vivo and
in vitro studies have established an association of microglial activation with the
pathogenesis of ALS and MS (Dickson et al., 1993; Raine, 1994).

The growing evidence that microglia may be a key player in the process of
neurodegeneration encouraged researchers to target microglia and inflammation as a
therapeutic intervention for neurodegenerative diseases. For example, Administration
of aminopyridazines is shown to both attenuate glial inflammation and result in
reduction of neuronal neurotoxicity in the murine intraventricular human Aβ 1-42
infusion model (Craft et al., 2004). In a separate study, non-steroidal antiinflammatory drug (NSAID) treatment in mice over-expressing Aβ was able to lower
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Aβ deposition, inhibit microglial activation, and provide neuroprotection (Yan et al.,
2003).

There has been some success with clinical studies investigating the effects of
anti-inflammatory therapy against cognitive decline in AD patients (Perry et al.,
2003). Many epidemiologic studies have indicated that the use of anti-inflammatory
drugs reduces the incidence and slows the progress of Alzheimer’s disease (McGeer
and McGeer, 1999). A prospective population-based cohort study of about 7000
individuals revealed that the relative risk of AD decreases to 0.2 with the use of
NSAIDs for more than 2 years (in t' Veld et al., 2001). It is possible that the target of
such anti-inflammatory drugs is microglia.

Evidence that taking NSAIDs may slow the progression or delay the onset of
AD indicates, at a minimum, that inflammation and microglia are critical for the
ongoing process of neurodegeneration in AD. A major unresolved question is
whether inhibition of these responses will be a safe and effective means of reversing
or slowing the course of disease.

1.2.5

Mechanisms of Microglial Activation
Microglia can be activated by two mechanisms: (1) direct stimulation of

microglia from environmental or endogenous toxins; (2) activation through a reactive
microgliosis process. In general, dying or damaged neurons have the potential to
activate microglia, regardless of how the neurons were damaged.

Reactive

microgliosis (Figure 1) is the process in which damaged neurons activate microglia
to initiate a self propelling cycle of neuron-death. There are diverse triggers that are
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able to activate microglia directly and stimulate their proliferation to exert their
neurotoxicity. These triggers (Figure 2) include immunological insult, such as LPS;
environmental toxins and endogenous disease proteins (Block and Hong, 2005).

Figure 1: Reactive microgliosis (Block and Hong, 2005)

LPS is a widely used as a powerful tool for the activation of microglia and
peripheral immune cells. Although LPS has no known direct toxic effect on neurons,
it activates microglia to release a host of neurotoxic factors to induce neuronal death
(Liu et al., 2002). Neurotoxins, such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) and 6-hydroxydopamine (6-OHDA), cause direct damage to dopaminergic
neurons and causes reactive gliosis. Activation of microglia in turn exacerbates the
neurodegenerative process (Wu et al., 2002). Some agents that are known to be
associated with various neurodegenerative diseases exhibit a “mixed mode”
mechanism of neurotoxicity, A and -synuclein protein. It appears that the overall
neurotoxic effect of these mixed mode toxins includes both direct neurotoxicity and
indirect toxicity through the activation of microglia (McMillian et al., 1994).
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Figure 2: Types of neurotoxins (Liu and Hong, 2003)

The intracellular signaling mechanism of microglial activation and
inactivation was not fully studied. It is possible that the unique collection of
membrane channels of microglia ,including the presence of an inward rectifying K+
channel and the absence of an outward rectifying K+ channel is one route by which
microglia may be sensitive to their ionic microenvironment (Kettenmann et al.,
1990). Furthermore, adenosine triphosphate (ATP) is rapidly released from cells
during acute degeneration and several studies suggest that a purinergic receptor
binding ATP may also rapidly activate microglia (Perry et al., 1995). It has been
shown that activated microglia express the transcription factor nuclear factor kappa B
(NF-κB) during immune-mediated activation (Kaltschmidt et al., 1994).
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1.2.6
1.2.6.1

Common Characteristics of M1 Microglial Activation
Release of Neurotoxic Factors
Across several toxins, it is clear that the first event is the production of

reactive oxygen species (ROS), which includes the extracellular superoxide anion
(Gao et al., 2002). The increase in the production of ROS is rapid, usually occurring
within minutes, and is typically measured in microglia 10–30 min after LPS addition.
The microglial ROS response is followed by the release of cytokines (such as TNF-α
and IL-1β), nitric oxide, and prostaglandin E2 that peaks around 6–12 h (Gao et al.,
2002). Experiments using different mutant mice deficient in NADPH oxidase, iNOS,
COX-2, or TNF-α receptors all resulted in reduced neurotoxicity (Wang et al., 2004),
indicating that the individual proinflammatory factors released are sufficient, but not
mandatory, for neurotoxicity.

1.2.6.2

NADPH Oxidase
NADPH oxidase is the predominant source of microglial extracellular ROS

production in response to multiple and diverse stimuli (Wu et al., 2005). NADPH
oxidase is a membrane-bound enzyme that catalyzes the production of superoxide
from oxygen. This enzyme is dormant in resting phagocytes but is activated when the
cell is activated (Babior, 2000).

Oxidative stress is a common characteristic shared across numerous
neurodegenerative diseases (Perluigi et al., 2005), suggesting a basic and similar
mechanism underlying diverse neurodegenerative pathology. Further, NADPH
oxidase is upregulated in neurodegenerative diseases such as PD (Wu et al., 2003).
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1.2.6.3

ROS and Proinflammatory Factors
Intracellular ROS are critical for the activation of microglia and the

enhancement of the production of proinflammatory factors. There is increasing
support that intracellular ROS can also function as second messengers to regulate
several downstream signaling molecules, including protein kinase C, mitogen
activated protein kinase (MAPK) and NF-κB (Konishi et al., 1997). Min and
coworkers in (2004) demonstrated that the production of IL-1β, TNF-α and iNOS are
attenuated by the addition of the NADPH oxidase inhibitor, diphenyleneiodonium.
Furthermore, NADPH oxidase inhibitors and catalase are shown to suppress LPSinduced expression of cytokines (IL-1β, IL-6, and TNF-α), iNOS expression, MAP
kinases, and NF-κB phosphorylation (Pawate et al., 2004).

Accumulating evidence supports that activation of NADPH oxidase
contributes to microglia-mediated neurotoxicity through two mechanisms: (1)
Production of extracellular ROS that is toxic to neurons. (2) Activation of Increasing
microglial intracellular ROS, which enhances the production of proinflammatory
factors that are toxic to neurons (Block and Hong, 2005).

1.3

Cytokines
Cytokines are a family of low molecular weight, multifunctional polypeptides

acting as humoral regulators that modulate the functional activities of individual cells
and tissues under normal, pathological and toxicological conditions. They are
primarily involved in host responses to disease or infection (Dinarello, 2000). They
act as mediators of inflammation and regulation of cell growth and differentiation.
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Originally called lymphokines and monokines to indicate their cellular sources, but it
became clear that the term “cytokine” is the best description, since nearly most
nucleated cells are capable of synthesizing these proteins and, in turn, of responding
to them (Dinarello, 2000). They include interleukins (IL), interferons (IFN), tumor
necrosis factors (TNF), chemokines and growth factors. Many cytokines show
synergistic or overlapping activities, and in some cases share related receptors
(Rothwell and Strijbos, 1995).

1.3.1

Proinflammatory and Anti-inflammatory Cytokines
Some

cytokines

clearly

promote

inflammation

and

are

called

proinflammatory cytokines (IL-1β, TNF-α, IL-6, and chemokines), whereas other
cytokines suppress the activity of proinflammatory cytokines and are called antiinflammatory cytokines (IL-3, IL-4, IL-10 and TGF-) (Kolesnick and Golde, 1994;
Smith et al., 2012; Viviani et al., 2004). A “balance” between the effects of
proinflammatory and anti-inflammatory cytokines is thought to determine the
outcome of disease, whether in the short term or long term. Some studies suggested
that susceptibility to a disease is genetically determined by the balance or expression
of proinflammatory or anti-inflammatory cytokines (Dinarello, 2000).

1.3.2

Expression and Action of Cytokines in the Brain
Cytokines have been involved in the modulation of several neurological

functions and dysfunctions. The numerous cytokines affecting the CNS have two
possible origins: (1) they originate from the peripheral immune organs and cross the
BBB, (2) they are produced by glial cells (astrocytes and microglia) and certain
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neurons. For many cytokines, glial cells seem to be the primary producers in the
CNS (Zhang and Zhu, 2011). The expression of most cytokines is tightly regulated
and these factors are usually produced only after cell activation in response to an
induction signal (Viviani et al., 2004). They are hardly detectable in the CNS under
physiological conditions, but both pro- and anti-inflammatory cytokines become
rapidly upregulated by pathological events, like Alzheimer’s disease, excitotoxicity,
exposure to neurotoxins, LPS injection or viral infection (Gabellec et al., 1995;
Marquette et al., 1996; Minami et al., 1991; Smith et al., 2012; Sriram et al., 2002).

1.4

Tumor Necrosis Factor Alpha (TNF-α)
TNF-α is a multi-functional potent proinflammatory cytokine that can

regulate many cellular and biological processes such as immune function, cell
differentiation, proliferation, apoptosis and energy metabolism. Its actions range
from an important role in lymphoid organ development and maturation of the
humoral immune response (Pasparakis et al., 1996), to its better known involvement
in the pathogenesis of infectious, inflammatory and autoimmune diseases (Guerder et
al., 1994; Vanden Berghe et al., 2014). TNF-α was originally discovered in the
mouse serum during endotoxemia and recognized for its anti-tumor activity
(Carswell et al., 1975). It is synthesized as a 26-kDa transmembrane monomer
(mTNF-α) that undergoes proteolytic cleavage by the TNF-α converting enzyme to
yield a 17-kDa soluble TNF-α molecule (s TNF-α). The proteolysis is mediated by
TNF-α converting enzyme (Black et al., 1997). Both sTNF-α and mTNF-α can affect
biological and metabolic responses, suggesting that mTNF-α may mediate paracrine
and autocrine signals, leaving sTNF-α to mediate endocrine effects (Grell et al.,
1999).
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Its role in the CNS was not observed until 1987, when microglia was found to
produce TNF-α (Frei et al., 1987). At present it is well established that apart from the
microglial cells, TNF-α can also be synthesized and released in the brain by
astrocytes and some populations of neurons (Probert, 2015; Viviani et al., 2004).

1.4.1

TNF-α Receptors
The pleiotropic actions of TNF-α are mediated through two distinct cell

surface receptors: TNFR1 (p55) and TNFR2 (p75) (Wajant et al., 2003). They are
membrane glycoprotein receptors that specifically bind TNF-α, but the two receptors
differ in their expression profiles, ligand affinity, cytoplasmic tail structure, and
downstream signaling pathway activation. Signaling of TNF-α requires that TNFRs
preassemble on the cell membrane as trimers prior to ligand binding. This
trimerization occurs through the intracellular cytoplasmic tail of the receptors (Chan
et al., 2000). TNF-α signaling through TNFR1 and TNFR2 can elicit a variety of
cellular responses depending on many factors including the metabolic state of the
cell and the adaptor proteins present in the cell. These differences result in a number
of responses including inflammation, proliferation, cell migration, apoptosis, and
necrosis (Eissner et al., 2004).

1.4.1.1

Cellular distribution of TNFRs
TNFR1 is expressed in most cell types, and can be activated by binding of

either sTNF- or mTNF-, with a preference for sTNF-; whereas TNFR2 is
expressed primarily by cells of the immune system and by endothelial cells, and is
preferentially activated by mTNF- (Grell et al., 1998). In the brain, both TNFRs are
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expressed by neurons and glia (Dopp et al., 1997). The differential patterns of
localization of TNFRs in neuronal and glial cells, their state of activation and the
down-stream effectors, all are thought to play an important role in determining
whether TNF-α will exert a beneficial or harmful effect on CNS (Figiel, 2008).

1.4.1.2

TNFR1-Mediated Signaling
Only TNFR1 contains a cytoplasmic death domain (DD) and may directly

induce apoptosis. Binding of the TNF trimer to the extracellular domain of TNFR1
permits the assembly of the TNFR1 signaling complex through the dissociation of
silencer of death domains (SODD) and subsequent binding the adaptor protein TNF
receptor-associated death domain (TRADD) (Ware et al., 1996). TRADD recruits
other adaptor proteins: receptor-interacting protein (RIP), TNF receptor-associated
factor 2 (TRAF2) and FAS-associated death domain (FADD) (Hsu et al., 1996).The
latter two proteins recruit key enzymes that are responsible for initiating TNFR1
signaling events. For instance, caspase-8 is recruited by FADD leading to the
formation of the death-inducing signaling complex (DISC), and triggering activation
of the executioner caspases through the extrinsic apoptosis pathway (SchneiderBrachert et al., 2004). Caspase-8 also triggers the intrinsic apoptosis pathway by
cleaving the proapoptotic Bcl-2 family members Bax and Bid to initiate
mitochondrial-induced apoptosis (Wang et al., 2006). On the other hand TRAF2
recruits cellular inhibitor of apoptosis protein-1 and 2 (cIAP-1 and cIAP-2), two antiapoptosis proteins that also have ubiquitin protein ligase activity. Moreover, TRAF2
may activate MAPK pathway leading to the activation of c-Jun N-terminal kinase
(JNK) that phosphorylates c-Jun, increasing its transcriptional activity. Finally, the
protein kinase RIP is critical to the activation of the transcription factor NF-κB
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(Walczak, 2011). Therefore TNF-α binding to TNFR1 may result in activation of
apoptosis, proliferation, or transcriptional activity (Figiel, 2008).

1.4.1.3

TNFR2-Mediated Signaling
Signaling through TNFR2 activates inflammatory and prosurvival signaling

pathways through recruitment of TRAF1 and TRAF2 adaptor proteins and
subsequent activation of cIAPs and the NF-κB pathway (Rao et al., 1995; Walczak,
2011). TNFR2 has also been shown to activate phosphatidylinositol 3-kinase
dependent signaling to promote neuron survival (Marchetti et al., 2004). TNFR2
does not contain a DD, and thus, unlike signaling through TNFR1, TNFR2 activation
does not directly lead to caspase activation. However, studies with TNF-α receptorspecific neutralizing antibodies showed that stimulation of TNFR2 relies on the
induction of endogenous, membrane-bound TNF-α, which subsequently activates
TNFR1 (Grell et al., 1999). TNFR2 can promote TNFR1 signaling by enhancing the
association between TNF- and TNFR1 via a ligand passing mechanism (Tartaglia
et al., 1993). Figure 3 summarizes the TNF-α signaling through both TNFR1 and
TNFR2.

1.4.2

TNF-α in the CNS
In

the

CNS,

TNF-α

is

considered

the

principal

mediator

of

neuroinflammation. TNF-α signaling have several important functions within the
CNS, including injury-mediated microglial and astrocyte activation, and regulation
of BBB permeability, febrile responses, glutamatergic transmission, and synaptic
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plasticity (Boulanger, 2009; Merrill, 1991; Santello et al., 2011; Stellwagen and
Malenka, 2006).

Figure 3: TNF-α signaling through TNFR1 and TNFR2 (Montgomery and Bowers,
2012)

1.4.3
1.4.3.1

TNF-α in Brain Disorders
Neurotoxic Effects of TNF-α
TNF-α can potentiate excitotoxicity by two mechanisms. In combination with

sub-threshold glutamate levels, TNF-α can potentiate glutamate excitotoxicity
directly through activation of glutamate-NMDA receptors (Zou and Crews, 2005)
and localization of AMPA receptors to synapses (Leonoudakis et al., 2004), and
indirectly by inhibiting glial glutamate transporters on astrocytes (Santello et al.,
2011).
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Elevated levels of TNF-α have been associated with the pathological effects
of a variety of infectious, neurological, neurodegenerative, and neurotoxic conditions
(Probert, 2015), including ischemia (Feuerstein et al., 1994), bacterial meningitis
(Leist et al., 1988), cerebral malaria (Grau et al., 1989), traumatic brain injury
(Goodman et al., 1990), multiple sclerosis (Raine et al., 1998), Alzheimer's disease
(Alvarez et al., 2007) and Parkinson's disease (Mogi et al., 2000).

TNF-α immunoreactivity has been reported on neurons, astrocytes, microglia,
and endothelial cells, and is present within perivascular spaces (Botchkina et al.,
1997). Administration of exogenous TNF-α markedly exacerbates ischemic injury in
vivo, and acute inhibition of TNF-α action, by administration of TNF-α soluble
receptor or a neutralizing antibody to TNF-α markedly attenuates ischemic brain
damage in rat and mouse (Barone et al., 1997). A number of preclinical and clinical
studies in various disease models and in chronic neurodegenerative conditions
suggest that targeting TNF-α action in the brain may be an attractive diseasemodifying strategy to slow progression or attenuate severity of the disease (McCoy
and Tansey, 2008).

1.4.3.2

Neuroprotective Effects of TNF-α
While several lines of evidence suggest a neurotoxic role for TNF- in the

CNS, it does not appear to be strictly neurotoxic. In addition to its key role in
maintaining CNS homeostasis, TNF-α is known to influence survival, differentiation,
proliferation, and growth. These features highlight a potential protective role for this
cytokine (Sriram and O'Callaghan, 2007). It is important to know that TNF-α do not
cause neuronal death in healthy brain tissue or normal neurons even at very high

24
doses (Venters et al., 1999). This failure to induce death directly may be because
TNF-α is not neurotoxic per se.

Several studies showed that TNF-α can protect against brain injury. It has
been shown to promote reparative remyelination in an experimental model of
demyelination (Plant et al., 2005). In this case, TNF-α appears to promote the
survival of oligodendrocytes, thereby, facilitating remyelination. Preconditioning
with TNF-α protected neurons against ischemic injury (Ginis et al., 2002;
Lambertsen et al., 2009), suggesting that TNF-α is involved in the development of
ischemic tolerance. TNF-α also mediates neuroprotection in response to acute nitric
oxide excitotoxicity (Turrin and Rivest, 2006).

Low doses of TNF-α had a neuroprotective effect on AMPA receptormediated excitotoxicity (Bernardino et al., 2005). In this study, the neuroprotection
was found to be mediated by TNFR2, whereas the exacerbating action on AMPA
toxicity was mediated by TNFR1. TNF-α also showed a protective role against Aβ
peptide toxicity in rat hippocampal cultures (Barger et al., 1995) when administered
before the toxic insults. More findings suggested that TNFR2 signaling protects
against excitotoxicity. Specifically, cortical neurons from mice that overexpress
TNF-α in the CNS were protected from glutamate toxicity as were wild type and
TNFR1-deficient mice pretreated with TNF-α or agonistic TNFR2 antibodies
(Marchetti et al., 2004). Consistent with those findings, neurons derived from
TNFR2-deficient mice were susceptible to both TNF-α and glutamate-induced death.
(Marchetti et al., 2004).
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These observations strongly suggest that one potential approach to lessen
adverse effects of anti-TNF therapies in the CNS may be to selectively target TNFR1
signaling with localized delivery of inhibitors which spare TNFR2-mediated
signaling. As sTNF-α signals preferentially through TNFR1, selective inhibition of
sTNF-α signaling may be advantageous. This approach may allow efficient
neutralization of sTNF-α in the desired region without eliciting collateral damage to
TNFR2/ mTNF-α-dependent processes in regions of the brain where mTNF-α has
important homeostatic functions. A second strategy is to increase TNFR2 expression
levels through gene therapy to allow protection of neuronal populations that are
highly sensitive to sTNF-α/TNFR1- mediated toxicity (McCoy and Tansey, 2008).

Some studies showed that TNFR1 and TNFR2 may have opposite effect on
neurons, with the former having damaging effect and the latter being neuroprotective
(Fontaine et al., 2002). Studies in mice lacking only one type of TNFRs revealed that
TNFR1 signaling pathway is more important than TNFR2 one in mediating
neuroprotective actions of TNF-α after acute brain insults (Lu et al., 2008). This
study showed that mice lacking TNFR1 exhibit more severe seizure activity,
hippocampal neurodegeneration and increased microglial activation, suggesting that
TNF-α exerts its protective role through TNFR1 signaling (Lu et al., 2008). In
addition, TNFR2 involvement in chemical-induced apoptosis of murine hippocampal
dentate granule neurons has been reported (Harry et al., 2008). In the latter study,
they employed trimethyltin (TMT), a well known neurotoxicant, to induce neuronal
injury accompanied by microglial activation and increased production of TNF-α.
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In (1996), Bruce and colleagues reported that mice deficient in both receptors
displayed greater neuronal damage following either ischemic or kainic acid induced
excitotoxic damage. They found that damage was accompanied by increased
oxidative stress as well as reduced level of manganese superoxide dismutase (MnSOD), so they suggested that TNF-α may play a beneficial role by stimulating
antioxidant pathway. On the other hand, mice lacking both TNFRs were protected
against the dopaminergic neurotoxicity of MPTP (Sriram et al., 2002). These
paradoxical findings (Figure 4) suggested that TNF-α was capable of mediating
differential effects in specific brain areas. While deficiency of TNF receptors
blocked MPTP neurotoxicity in the striatum, the lack of these receptors rendered the
hippocampus vulnerable to injury (Sriram et al., 2006).

Figure 4: Paradoxical effects of TNF-α in different brain regions (Sriram and
O'Callaghan, 2007)
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1.5

Kainic Acid Induced Neurodegeneration Model
Glutamate is the principal excitatory neurotransmitter in the mammalian

CNS. It is associated with cognition, memory, and movement (Cacabelos et al.,
1999) and it is involved in early development of the human CNS (Bardoul et al.,
1998). Over stimulation of glutamate receptors causes neuronal injury or death by a
mechanism termed excitotoxicity. Excitotoxicity is thought to play a key role in the
induction of neuronal cell death occurring after brain trauma and in neurological
disorders, including neurodegenerative diseases (Meldrum, 2000). Activation of
glutamate receptors causes an influx of sodium and calcium ions. The high
intracellular levels of calcium then initiate signaling cascades within susceptible
neurons that cause neuronal death (Choi, 1988).

Excitotoxic cell death is commonly induced experimentally by the
administration of kainic acid (KA), a potent agonist of the AMPA/kainate class of
ionotropic glutamate receptors. Systemic administration of KA in rodents results in
recurrent seizures and subsequent degeneration of selective populations of neurons in
the hippocampus, specifically CA3 and CA1 regions (Sperk et al., 1983). KA
administration was shown to be associated with increased production of reactive
oxygen species (ROS), mitochondrial dysfunction, activation of microglia, and
disruption of calcium signaling (Benkovic et al., 2006).

These studies suggest that KA-induced excitotoxicity can be used as a model
for elucidating mechanisms underlying inflammation and oxidative stress in
neurodegenerative diseases (Wang et al., 2005; Zhang and Zhu, 2011). However,
Schauwecker and Steward in (1997) showed that certain commonly used strains of
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mice, specifically C57BL/6 and BALB/c, are resistant to KA-induced neuronal
death. Subcutaneous doses of KA less than 40 mg/kg do not result in neuronal
damage in the hippocampus of C57BL/6 mice. Doses higher than 40 mg/ kg, cause
mild histopathological changes in the mouse hippocampus, but only at the expense of
the survival rate, which is less than 25% (Schauwecker and Steward, 1997). As
C57BL/6 mice are used for most transgenic studies, then resistance to KA-induced
neuronal death makes it difficult to study KA-induced neurodegeneration in
transgenic and knockout mice. Thus, a model of intranasal administration of KA was
adopted and was found to be effective in these mice strains, specifically C57BL/6
mice (Chen et al., 2002; Zheng et al., 2011).

1.6

Research Problem and Rationale for the Study
In brief, TNF-α is a proinflammatory cytokine that exerts both homeostatic

and pathophysiological roles in the CNS. TNF-α acts as a key player in the initiation
and orchestration of inflammation in the periphery as well as in the CNS (Probert,
2015). Several reports suggested a neurotoxic role for TNF-α. High levels of TNF-α
have been observed in several CNS injuries such as ischemia, trauma, infection,
neurodegeneration, and chemically induced neurotoxicity (Alvarez et al., 2007;
Feuerstein et al., 1994; Goodman et al., 1990; Leist et al., 1988; Mogi et al., 2000).
TNF-α also was found to potentiate excitotoxic injury (Barone et al., 1997). Whether
TNF-α signaling actively contributes to or limits neuronal injury in these disorders
was not established. Most of these reports concluded that targeting TNF-α signaling
would be a good therapeutic target to modify the progress of neurodegeneration
(McCoy and Tansey, 2008). On the other hand, several studies suggest
neuroprotective properties for TNF-α. It was found that absence of TNF-α worsens
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CNS infections (Figiel, 2008). In addition, knockout mice lacking both TNF
receptors or TNFR1 receptors only showed exacerbated ischemic and excitotoxic
brain damage (Bruce et al., 1996; Fontaine et al., 2002; Lu et al., 2008). Furthermore,
dysregulated TNF-α signaling has been implicated in the initiation and/or
progression of a number of human diseases (Figiel, 2008; Probert, 2015). These
studies provided an important factor to be considered for therapeutic approaches
involving complete neutralization of TNF-α for treatment of various disorders, such
as rheumatoid arthritis, because these treatments my result in increased susceptibility
to neuronal injury. Hence, a controversy exists regarding the role of TNF-α in
neurodegeneration.

We have to consider that these studies involved different models of
neurodegeneration targeting different areas of the brain and to appreciate different
cellular composition (neuron/microglia) and receptor expression (TNFR1/TNFR2).
Some of these studies are in vitro studies lacking the interaction between neurons and
surrounding glial cells. In addition, most of these studies showed different degrees of
TNF-α signaling inhibition with very few studies using TNF-α knockout mice.

In KA-induced neurotoxicity model, most of studies were performed at one
or two time points (3 days, 5 days or maximum 7 days) (Zhang et al., 2007; Zhang et
al., 2012; Zhang et al., 2008). Thus, they observed the effects of TNF-α at theses
time points but at the same time they may miss other effects in very early or late time
points.
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In this thesis, we wanted to be specific, focusing on the role of TNF-α in
hippocampal neurodegeneration. We applied intranasal kainic acid induced
neurodegeneration model for the first time in TNF-α Ko mice. We also covered a
wide range of time points (0.5 and 4 hr as well as 1, 3, 5, 15 and 30 days) to catch
very early changes as well as delayed ones in the course of the hippocampal
neurodegeneration process.
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1.7

Hypothesis
The hypothesis of this study is that TNF-α exerts protection for hippocampal

neurons, hence removal of TNF-α will worsen hippocampal neurodegeneration.

1.8

Aims of the Study
The main objective of this study is to clarify the neuroprotective role of TNF-

α in kainic acid induced hippocampal neurodegeneration.

Specific aims:
1. To establish a model of neurodegeneration in male TNF-α knockout mice
and C57BL/6 mice using intranasal administration of KA.
2. To follow up the neurodegeneration process at different time points (0.5
and 4 hr as well as 1, 3, 5, 15 and 30 days) post KA treatment.
3. To investigate the impact of the presence and absence of TNF-α on
learning, memory and behavior of mice in KA-induced neurodegeneration.
4. To investigate the impact of the presence and absence of TNF-α on
neuronal cell death and microglial activation in mice with KA-induced
neurodegeneration.
5. To investigate the impact of the presence and absence of TNF-α on
oxidative stress, cytokines and growth factors in mice with KA-induced
neurodegeneration.
 To find a possible mechanism(s) for the role of TNF-α in KA-induced
neurodegeneration
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Chapter 2: Materials and Methods
This study was approved by the Research Ethics Committee (Institutional
Review Board) at the College of Medicine and Health Sciences, UAE University.

2.1

Animals
Adult age-matched male TNF-α knockout (Ko) (n = 170) and C57BL/6 wild

type (Wt) mice (n = 130), (6 to 8 weeks old) are used in the present study. The TNFα Ko mice had been generated through targeted disruption of the TNF-α gene and
being backcrossed to the C57BL/6 strain (Marino et al., 1997). It was reported that
females as well as aged C57BL/6 mice were more sensitive to KA-induced
neurodegeneration (Zhang et al., 2008). In order to avoid any confounding factors we
preferred to use male adult mice in this study. All mice were housed on a 12 hr lightdark schedule with water and food available ad libitum. The KA induced excitotoxic
model in mice was approved by the CMHS Research Animal Ethics Committee,
UAEU. All efforts were made to minimize the number of animals used and their
sufferings.

2.2

KA Administration and Seizure Activity Assessment
Male TNF-α Ko and C57BL/6 Wt mice (n = 50) were partially anesthetized

with Isoflurane and held on their backs by hand. KA dissolved in distilled water, (10
mg/1.3 ml) was slowly and gently dropped by micropipette into the nostrils of the
mice at a dose of 40 mg/kg body weight (Chen et al., 2002; Lu et al., 2008). A total
of 40 l of KA solution was delivered over 10 min (20 l for each naris, with a break
of 2 min between instillation into each nostril). For volumes of more than 40 l of
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KA, the first 40 l of KA was administered over 10 min, with a break for 10 min.
The next 40 l of KA was then administered. Age- and body weight-matched control
TNF-α Ko and C57BL/6 Wt mice received the same amount of vehicle (Distilled
Water) intranasally. Mice were observed by two different examiners continuously for
5 hours to record the onset and extent of seizure activity. Seizures were rated
according to the criteria described by Ben-Ari (1985) with modifications: 0, normal;
1, immobilization; 2, rearing and falling; 3, seizure for less than 1 hr; 4, seizure for 13 hr; 5, seizure for more than 3 hr; and 6, death.

Different groups of mice from both strains are kept for different time points;
0.5 hr and 4 hr as well as 1, 3, 5, 15 and 30 days after KA treatment, to investigate
the time course and the role of TNF-α in hippocampal neurodegeneration.

2.3

Behavioral Assessments
TNF-α Ko mice and Wt mice (n = 15-22) are exposed to three behavioral

tests before and after KA treatment according to the experimental design shown in
(Figure 5). All behavioral tests were carried out between the hours from 9:00 to
15:00 in a dimly lit room, into which the animals were brought in their home cage 1
hr prior to the start of the test.
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Figure 5: Experimental Design for Behavioral Tests

2.3.1

Elevated Plus Maze Test (EPM)
This test gives a measure of anxiety level and it is done 3 days before KA

treatment and 3 days before sacrificing the mice of both strains. It is based on the
assumption that normally mice prefer a closed environment to an open space (Pellow
et al., 1985). The EPM apparatus consists of two open (30 × 5 cm) and two closed
arms of the same size Plexiglas, with 15 cm high walls. The arms were constructed
of white acrylic radiating from a central platform (5 × 5 cm) to form a plus sign. The
entire apparatus was elevated 40 cm above the floor. The floor of the arms was
smooth. The test was initiated by placing each mouse on the central platform facing
one of the open arms. An arm entry was defined as the entry of all four paws into the
arm. The number of entries into the open and closed arms and the time spent on the
open and closed arms were recorded over a 5-min test period. The maze apparatus
was cleaned with water then 70% ethanol and dried after each trial.
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2.3.2

Open Field Test
Open-field activity was measured two days before KA treatment and two

days before sacrificing the mice of both strains. The open field test was used to
measure exploratory behavior and spontaneous motor activity of the animals
(Denenberg, 1969). The apparatus consisted of a transparent acrylic plastic
(Plexiglas) box (35x35x17 cm) in which the floor was subdivided into 64 equal
squares (4.38x4.38 cm). The box was placed under white light, and a mouse was
gently placed in the center of the box. Locomotor activity and rearing were recorded
every 3 min for a period of 9 min. Locomotor activity was evaluated by counting the
number of times the mouse crossed the floor squares with both hind paws. Rearing
was evaluated by counting the number of times the mouse was vertical with the
forepaws raised. The enclosure was washed with water and then 70% ethanol
between each test.

2.3.3

Y-Maze Test
Spontaneous alternation performance was tested using a symmetrical Y-

maze. The Y-maze was used for identification of discrimination learning, spatial
alteration tasks, and working memory of rodents (Hefco et al., 2003). This test is
done one day before KA treatment and one day before sacrificing the mice of both
groups. Each mouse was placed at the end of one arm of the Y-maze and was
allowed to explore freely through the maze during a 6-min session. The sequence and
total number of arms entered were recorded. Arm entry was considered to be
complete when the hind paws of the mouse had been completely placed in the arm.
The spontaneous alternation score (percentage) was calculated as the number of
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alternations (i.e., consecutive entries into all three arms) divided by the total possible
of alternations (i.e., total number of arms − 2) and multiplied by 100.

2.4

Histopathological Analysis
At the end of different time points experiments, all mice (n = 7-9) were

anesthetized with sodium pentobarbital and transcardially perfused with phosphatebuffered saline (PBS) followed by 4% paraformaldehyde. Brains were extracted,
fixed in 4% paraformaldehyde and kept in 10% sucrose until being frozen. Coronal
sections showing the hippocampus area from -1.15, - 1.94 and - 2.80 mm,
respectively, relative to the bregma were prepared according to the information in
Franklin's brain atlas. At least 3 sections in the hippocampus area from each animal
were stained by Fluoro-Jade B (FJB) to evaluate degenerating neurons.

2.5

Immunohistochemistry of Brain Sections
Fixed frozen hippocampal sections were prepared as described for

histopathological analysis. At least 3 sections in the hippocampus area from each
animal (n = 7-9) were used for each antibody staining. After washes with Tris
buffer, the sections were blocked by "protein block" at room temperature for 30 min.
Subsequently, they were exposed to rabbit antibodies to ionized calcium binding
adaptor molecule-1 (Iba-1), rabbit antibodies to glial fibrillary acidic protein (GFAP)
and rabbit antibodies against neuronal nuclear antigen (NeuN), followed by staining
with either fluorescent (For GFAP) or the avidin-biotin technique (Iba-1 and NeuN).
Omission of primary antibodies served as negative control.
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2.6

Hippocampal Tissue Homogenate
At the end of different time points, all mice (n = 9-14) were anesthetized with

sodium pentobarbital. Brains were extracted; hippocampi are dissected and kept
immediately in liquid nitrogen, then stored in −70 °C until being analyzed.
Hippocampal samples were homogenized (1:10 W/V ratio) in ice-cold Thermo
protein extraction reagent® (T-PER) buffer, supplanted with 1:100 protease inhibitor
cocktail. After sonication for 5×3 s, the samples were incubated for 30 minutes on
ice to facilitate cross-linking, then centrifuged at 15,000 rpm (eppendorf® 5417R)
for 30 min at 4 °C and the supernatant was collected and stored at −70 °C until use.

2.7

Cytokine Analysis
Protein concentrations were determined by using the protein assay kit and the

levels of cytokine (TNF-α, IL-6, IL-12, Il-1 and IL-10) were assessed using ELISA
(Mosmann and Fong, 1989). Briefly, standard 96-well ELISA plates (NUNC,
Roskilde, Denmark) were incubated with the captured antibody, which binds the
cytokine of interest, at 4 °C overnight. The next day the plates were blocked by
incubation for 2 hr at RT with 1% bovine serum albumin in PBS. Serial dilutions of
known amounts of standard protein ranging from 0 to 2,000 pg/ml were applied in
duplicate for the standard curve. Wells containing the standard proteins and
supernatants of hippocampal tissue homogenates were incubated at 4 °C overnight as
specified by the protocol. They were then incubated with the corresponding
biotinylated detecting antibody for 1 hr at RT. An avidinylated antibody conjugated
to horseradish peroxidase (HRP) as a tertiary reactant was incubated for 30 min at
RT. Tetramethylbenzidine at 100 μl per well was used to develop color. The reaction
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was terminated with 2N sulfuric acid and the absorbance was recorded at 450 nm in a
plate reader within 10 min after stopping of the reaction.

2.8

Oxidative Stress Analysis

2.8.1

Malondialdehyde (MDA)
Malondialdehyde (MDA) is a naturally occurring product of lipid

peroxidation. Lipid peroxidation is used as an indicator of oxidative stress in cells
and tissues. The measurement of Thiobarbituric Acid Reactive Substances (TBARS)
is a well-established method for screening and monitoring lipid peroxidation (Yagi,
1998).

Cayman’s TBARS Assay Kit was used to assay lipid peroxidation in
hippocampal tissue homogenates. An MDA-TBA adduct (Equation 1) was formed by
the reaction of MDA and Thiobarbituric Acid (TBA) when placed in boiling water of
90-100°C and acidic conditions. The adduct was then measured colorimetrically at
540 nm wavelength using the plate reader Infinite M200pro (Tecan®).

Equation 1: MDA-TBA adduct

39
2.8.2

Nitric Oxide Production
Nitric oxide (NO) is produced in trace quantities by neurons, endothelial

cells, platelets and neutrophils in response to homeostatic stimuli. NO is also
produced by other cells (macrophages, fibroblasts, hepatocytes) in micromolar
concentrations in response to inflammatory or mitogenic stimuli. The final products
of NO in vivo are nitrite (NO2-) and nitrate (NO3-). The best index of total NO
production is the sum of both NO2- and NO3-.

Cayman’s Nitrate/Nitrite Fluorometric Assay kit provides measures total
nitrate/nitrite concentration in a simple two step process (Equation 2). The first step
is the conversion of nitrate to nitrite utilizing nitrate reductase. The second step is the
addition of 2,3-diaminonaphthalene, provided as an acidic solution, followed by
sodium hydroxide which enhances the detection of the fluorescent product, 1(H)naphthotriazole (Misko et al., 1993).

Equation 2: Scheme of nitrate/nitrite assay
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2.8.3

Glutathione (GSH)
Reduced Glutathione (GSH) is the key antioxidant in animal tissues. It is

present inside cells mainly in the reduced form (90-95% of the total glutathione).
Intracellular GSH status appears to be a sensitive indictor of the overall health of a
cell, and of its ability to resist toxic challenge. High levels of GSH in the cell may
indicate pathological changes.

The glutathione assay kit from Sigma-Aldrich® was used to measure the
level of total glutathione (GSSH + GSH) in the hippocampal tissue homogenate. The
samples were first deproteinized with 5% 5-Sulfosalicylic Acid Solution, next
centrifuged to remove the precipitated protein, and then assayed for glutathione.

GSH was oxidized by the sulfhydryl reagent 5,5′-dithio-bis(2-nitrobenzoic
acid) (DTNB) to form the yellow derivative 5′-thio-2-nitrobenzoic acid (TNB) and
glutathione disulfide (GSSG). The GSSG formed was recycled to GSH by
glutathione reductase in the presence of NADPH (Equation 3) and the TNB was
measured spectrophotometrically (Akerboom and Sies, 1981). The plate reader was
set at a wavelength of 412 nm, with kinetic reading at 1 minute interval for 5
minutes.

Equation 3: GSH assay
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2.8.4

Catalase (CAT)
Catalase (CAT) is a ubiquitous antioxidant enzyme that is present in most

cells. CAT is involved in the detoxification of hydrogen peroxide (H2O2), a reactive
oxygen species, which is a toxic product. This enzyme demonstrates catalytic activity
and peroxidatic activity (Equation 4).

Equation 4: Catalase activity

Cayman’s Catalase Assay Kit® was employed to measure CAT activity in
tissue homogenates of the hippocampus. It utilized the peroxidatic function of CAT
for determination of enzyme activity (Wheeler et al., 1990). The method was based
on the reaction of CAT with methanol in the presence of H2O2. Formaldehyde was
produced and measured colorimetrically with 4-amino-3-hydrazino-5-mercapto1,2,4-triazole (Purpald) as the chromogen. It specifically formed a bicyclic
heterocycle with aldehydes, which upon oxidation changed from colorless to a purple
color. The absorbance was read at 540 nm wavelength.

2.8.5

Superoxide Dismutase (SOD)
Superoxide dismutase (SOD) is a metalloenzyme that is widely distributed in

both plants and animals. It occurs in high concentrations in brain, liver, heart,
erythrocytes and kidney. It catalyzes the dismutation of the superoxide anion to
molecular oxygen and hydrogen peroxide (Equation 5). The amount of SOD present
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in cellular and extracellular is crucial for the prevention of diseases linked to
oxidative stress.

Equation 5: Superoxide Anion Dismutation

Cayman’s Superoxide Dismutase Assay Kit utilizes a tetrazolium salt for
detection of superoxide radicals generated by xanthine oxidase and hypoxanthine
(Equation 6). One unit of SOD is defined as the amount of enzyme needed to exhibit
50% dismutation of the superoxide radical (Sandstrom et al., 1994). The SOD assay
measures all three types of SOD (Cu/Zn, Mn and Fe-SOD).

Equation 6: Scheme of the SOD assay

2.9

Growth Factor Analysis
Nerve growth factor-NGF) is involved in the maintenance of the

sympathetic and sensory nervous systems. It exerts a number of different effects on
neurons, such as development, survival, and differentiation. Neurons that fail to
obtain sufficient NGF die by apoptosis. Insulin like growth factor-I (IGF-I), a
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mediator of growth hormone actions, has also been shown to be an important
regulator of cell metabolism, differentiation, and survival.

A DuoSet ELISA from R&D Systems assay was used for the quantitative
measurement of these growth factors in hippocampal tissue homogenate (Crowther,
1995). It employed a specific antibody coated on a 96-well plate. The growth factors
present in a sample was bound to the wells by the immobilized antibody. Later,
biotinylated detection antibody was added followed by HRP-conjugated streptavidin.
The addition of the substrate solution (1:1 Tetramethylbenzidine and H2O2) allowed
color development in proportion to the amount of the growth factor bound. Finally,
the Stop Solution (2N sulfuric acid) changed the color from blue to yellow, and the
intensity of the color was measured at 450 nm.

2.10

Western Blotting for NFκB and AKT
The

hippocampal

supernatants

were

electrophoresed

on

a

12%

polyacrylamide gel and transferred to nitrocellulose membranes. The membranes
were then blocked in 5% non fat dry milk in PBS/Tween-20 for 1 hr at RT with
gentle agitation. After blocking, the membranes were incubated with appropriate
primary antibody, rabbit anti-mouse NFκB, rabbit anti-mouse AKT (Protein kinase
B) or rabbit anti-mouse β-actin, overnight at 4°C. After extensive washing in
PBS/Tween-20, membranes were incubated with peroxidase-conjugated secondary
antibodies for 1 hr at RT. The membranes were rinsed again. Enhanced
chemiluminescent Western blotting detection reagents were used for exposure
according to the manufacturer’s instructions. Densitometric analysis was performed
using the Image J program. Results were presented as “relative densities to β-actin”.
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2.11

Determination of NFκB Levels by ELISA
The levels of NFκB were assessed using the commercial provided NFκB/p65

ActivELISATM Kit (Imgenex Corporation, USA) (Shi et al., 2014). Briefly, standard
96-well flat bottom NUNC-Immuno maxisorp ELISA plates (NUNC, Roskilde,
Denmark) were incubated with the captured antibody at 4 °C overnight. In the next
day, the plates were blocked by incubation for 1 hr at RT with 1% Bovine Serum
Albumin (Sigma) in PBS. Serial dilutions of standard protein ranging from 0 to
10,000 ng/ml were applied in duplicate for the standard curve. Wells containing the
standard proteins and supernatants of hippocampal tissue homogenates were
incubated at 4 °C overnight as specified in the protocol. The plate was then incubated
with the detecting antibody for 1 hr at RT. The Alkaline phosphatase (AKP)Conjugated Secondary antibody as a tertiary reactant was incubated for 1 hr at RT.
The p-nitrophenylphosphate Substrate was used to develop color and the absorbance
was recorded at 405 nm in a plate reader within 30 min. The NFκB levels were
evaluated by comparison with the regression curve for standard.

2.12

Data Presentation and Statistics
Each set of data was presented as mean value ± standard error of the mean

(SEM). The one-factor analysis of variance (ANOVA) and Bonferroni post test were
used to compare values within groups. Student’s t-test was used to compare values
between groups in behavioral tests. All tests were two-tailed, and the level of
significance was set to p <0.05. Graphics and calculations were performed using
GraphPad PRISM version 5.0, and SPSS Version 19.0.
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Chapter 3: Results
3.1

Seizure Activity
After intranasal kainic acid (KA) treatment, both wild type (Wt) and TNF-α

knockout (Ko) mice manifested catatonic and staring behavior within few minutes,
followed by myoclonic twitching and frequent rearing and falling. Within 20–30 min
of the administration of KA, all mice displayed seizures. After the seizure activity
ceased, the surviving mice of both groups assumed a hunched posture, were
immobile for another few hours, and recovered in a similar way.
Seizures were rated based on the criteria described by Ben-Ari (1985) with
some modifications as follows:


0, normal;



1, immobilization;



2, rearing and falling;



3, seizure for less than 1 hr;



4, seizure for 1-3 hr;



5, seizure for more than 3 hr; and



6, death.

The results showed that the onset of seizure activity was significantly earlier
in TNF-α Ko mice compared to Wt mice. In addition, the seizures of the TNF-α Ko
mice were significantly longer lasting than those of the Wt mice (Figure 6). Watertreated Wt and TNF-α Ko mice did not show any symptoms.
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Figure 6: Onset of Seizures and Seizure Scores for Wt and TNF-α Ko mice after
intranasal administration of KA
Data represent the Mean ± SEM, (n = 50), ** Significant from Wt at P<0.01, ***
Significant from Wt at P<0.001.

3.2

Behavioral Tests
Both TNF-α Ko and Wt mice were exposed to three behavioral tests before

and after treatment with either water or KA at different time points. These behavioral
tests are Elevated Plus Maze (EPM), Open Field test and Y-Maze. Initially, water
treated Wt and TNF-α Ko mice did not show any significant behavioral changes in
the tests and the results were comparable to those of untreated mice.

3.2.1

Elevated Plus-Maze
In Elevated Plus-Maze (EPM), the following parameters were recorded for

each mouse over a period of 5 min: 1) number of entries into open arms; 2) number
of entries into closed arms; 3) time spent in open arms; 4) time spent in closed arms;
5) number of observations of head dipping over sides of open arms; 6) number of
risk assessment behaviors; and 7) number of observations of feces in 5 min (Figure

47
7). This test is performed for all mice 3 days before KA treatment and 5, 15 and 30
days after KA treatment. Usually normal mice prefer to stay more in the closed arms.

Following KA treatment, Both Wt and TNF-α Ko mice showed a significant
changed behavior compared with those observed before KA treatment. They showed
increased frequency and duration in open arms and decreased frequency in closed
arms specifically at 5 and 15 days post KA treatment. At 30 days post KA treatment,
TNF-α Ko mice significantly stayed more time in the open arms, while the Wt mice
spent more time in closed arms and showed lower frequency and duration in open
arms (Fig. 7 A-D). At all time points, both Wt and TNF-α Ko mice showed
decreased head drops in open arms (a measure of exploration as well) and risk
assessment behavior compared with those observed before KA treatment (Fig. 7 EF). However, TNF-α Ko mice showed significantly decreased counts of risk
assessment 30 days post KA treatment compared to Wt mice. The number of feces
during the test period (5 min) is an additional measure for the degree of anxiety that
was significantly increased in TNF-α Ko mice 5, 15 and 30 days post KA treatment
compared to respective KA treated Wt groups (Fig. 7G). Taken together, these
results showed changed risk assessment performance and decreased exploration in
the TNF-α Ko mice on the EPM compared to KA treated Wt mice, specifically at 30
days post KA treatment.

3.2.2

Open Field
The open-field test is performed for all mice before KA treatment and 3, 5, 15

and 30 days after KA treatment. Both locomotion and rearing are recorded for all
mice over a period of 9 min.
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Figure 7: Elevated Plus Maze Parameters for Wt and TNF-α Ko mice before and
after KA treatment
Data represent the Mean ± SEM, (n = 15-22), Vehicle = Distilled Water
* Significant from Wt Control at P<0.05, ** Significant from Wt Control at P<0.01, ***
Significant from Wt Control at P<0.001, # Significant from Ko Control at P<0.05, ##
Significant from Ko Control at P<0.01, ### Significant from Ko Control at P<0.001, $
Significant from respective Wt KA treated at P<0.05, $$ Significant from respective Wt
KA treated at P<0.01.
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KA treatment resulted in a state of hyperactivity in Wt and TNF-α Ko mice in
the form of increased locomotion and rearing counts compared with those observed
before KA treatment. The highest level of locomotion activity was observed 3 days
post KA treatment. TNF-α Ko mice showed significantly more locomotion activity
compared with KA treated Wt mice at 3 days and 30 days post KA treatment (Figure
8). Both TNF-α Ko and Wt mice showed increased exploratory activity as evident by
increased rearing count at 3, 5, 15, and 30 days post KA treatment compared with the
rearing activity observed before KA treatment (Figure 9). The highest level recorded
for rearing activity was 3 days post KA treatment.

3.2.3

Y-Maze
In a Y-maze test, the number of arm entries as well as the percent of

successful alternation between arms were recorded for all mice before KA treatment
and 3, 5, 15 and 30 days after KA treatment. Both KA treated TNF-α Ko and Wt
mice showed more arm entries compared with those observed before KA treatment
(Figure 10). This observation is in line with the hyperactivity observed in the Open
Field test. Similarly, the highest arm entries count was observed in both groups 3
days post KA treatment (Fig. 10 A-C). On the other hand, both KA treated TNF-α
Ko and Wt mice exhibited decreased successful alternation at 3 and 5 days post KA
treatment compared to those observed before KA treatment. At 15 and 30 days post
KA treatment, TNF-α Ko mice still showed decreased successful alternation while
Wt mice showed improved levels of alternation that is comparable to those obtained
before KA treatment. Percent alternation of TNF-α Ko mice at 30 days post KA
treatment is significantly lower compared to the respective KA treated Wt mice (Fig.
10 D).
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Figure 8: Locomotion count in Open Field Test for Wt and TNF-α Ko mice before
and after KA treatment
Data represent the Mean ± SEM, (n = 15-22), Vehicle = Distilled Water
* Significant from Wt Control at P<0.05, ** Significant from Wt Control at P<0.01, ***
Significant from Wt Control at P<0.001, ## Significant from Ko Control at P<0.01, ###
Significant from Ko Control at P<0.001, $ Significant from respective Wt KA treated at
P<0.05.
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Figure 9: Rearing count in Open Field Test for Wt and TNF-α Ko mice before and
after KA treatment
Data represent the Mean ± SEM, (n = 15-22), Vehicle = Distilled Water
* Significant from Wt Control at P<0.05, ** Significant from Wt Control at P<0.01, ***
Significant from Wt Control at P<0.001, # Significant from Ko Control at P<0.05, ##
Significant from Ko Control at P<0.01, ### Significant from Ko Control at P<0.001.
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Figure 10: Y-Maze test for Wt and TNF-α Ko mice before and after KA treatment
Data represent the Mean ± SEM, (n = 15-22), Vehicle = Distilled Water
* Significant from Wt Control at P<0.05, ** Significant from Wt Control at P<0.01, ***
Significant from Wt Control at P<0.001, # Significant from Ko Control at P<0.05, ##
Significant from Ko Control at P<0.01, ### Significant from Ko Control at P<0.001, $
Significant from respective Wt KA treated at P<0.05.
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3.3

Hippocampal Cytokine Levels
Cytokine levels were measured in the hippocampal supernatants of control

untreated, water treated and KA treated TNF-α Ko and Wt mice at different time
points (0.5 hr, 4 hr, 1, 3, 5, 15 and 30 days). Water treated Wt and TNF-α Ko mice
showed comparable values to those of control untreated mice.

3.3.1

TNF-α
Wt mice exposed to KA treatment exhibited a significant increase in the

levels of TNF-α in the hippocampus 0.5 and 4 hr as well as 1, 3 and 5 days post KA
treatment compared to their respective untreated controls. The hippocampal TNF-α
returned to normal levels at 15 and 30 days post KA treatment (Figure 11).
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Figure 11: Hippocampal TNF-α levels in Wt and TNF-α Ko mice before and after
KA treatment
Data represent the Mean ± SEM, (n = 9-14), Vehicle = Distilled Water
* Significant from Wt Control at P<0.05, ** Significant from Wt Control at P<0.01, ***
Significant from Wt Control at P<0.001.
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3.3.2

IL-6
TNF-α Ko and Wt mice exposed to KA treatment exhibited a significant

increase in the levels of IL-6 in the hippocampus 0.5 and 4 hr post KA treatment
compared to their respective untreated controls. During this period, most of the mice
exhibited seizures. The hippocampal IL-6 levels returned to normal levels at 1, 3, 5,
15 and were significantly decreased at 30 days post KA treatment in TNF-α Ko mice
(Figure 12).
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Figure 12: Hippocampal IL-6 levels in Wt and TNF-α Ko mice before and after KA
treatment
Data represent the Mean ± SEM, (n = 9-14), Vehicle = Distilled Water
* Significant from Wt Control at P<0.05, ** Significant from Wt Control at P<0.01, #
Significant from Ko Control at P<0.05, ## Significant from Ko Control at P<0.01, ###
Significant from Ko Control at P<0.001, $ Significant from respective Wt KA treated at
P<0.05.
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3.3.3

IL-1β
Similar to hippocampal IL-6 levels, TNF-α Ko and Wt mice exposed to KA

treatment exhibited a significant increase in the levels of IL-1β in the hippocampus
0.5 and 4 hr post KA treatment compared to their respective untreated controls.
During this period, most of the mice exhibited seizures. The hippocampal IL-1β
levels returned to normal levels at 1, 3, 5, 15 and 30 days post KA treatment (Figure
13).

30

IL-1 (pg/mg hippocampus)

* #

*

Wt
#

Ko

25

20
15
10
5
0

No KA

KA treated

Figure 13: Hippocampal IL-1β levels in Wt and TNF-α Ko mice before and after KA
treatment
Data represent the Mean ± SEM, (n = 9-14), Vehicle = Distilled Water
* Significant from Wt Control at P<0.05, # Significant from Ko Control at P<0.05.
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3.3.4

IL-12
An elevation in the levels of hippocampal IL-12 was observed at 0.5 and 4 hr

post KA treatment in KA treated TNF-α Ko and Wt mice compared to the respective
untreated controls. This increase is followed by a significant decrease that happened
earlier in TNF-α Ko mice (1 day post KA) compared to Wt mice (3 days post KA).
At 5, 15 and 30 days post KA; the levels of IL-12 in Wt mice were comparable or
significantly less than the normal levels. The IL-12 levels in TNF-α Ko mice
returned to normal levels at 3 and 5 days post KA treatment, however they were
significantly lower than their respective untreated controls and KA treated Wt mice
at 15 and 30 days post KA treatment (Figure 14).
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Figure 14: Hippocampal IL-12 levels in Wt and TNF-α Ko mice before and after KA
treatment
Data represent the Mean ± SEM, (n = 9-14), Vehicle = Distilled Water
* Significant from Wt Control at P<0.05, ** Significant from Wt Control at P<0.01, ***
Significant from Wt Control at P<0.001, # Significant from Ko Control at P<0.05, ###
Significant from Ko Control at P<0.001, $$ Significant from respective Wt KA treated
at P<0.01, $$$ Significant from respective Wt KA treated at P<0.001.
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3.3.5

IL-10
The basal levels of hippocampal IL-10 were significantly lower in control and

water treated TNF-α Ko mice compared to control and water treated Wt mice. Half
an hour post KA treatment, TNF-α Ko mice showed a significant elevation in the
levels of hippocampal IL-10 compared to their respective untreated controls. The
levels of hippocampal IL-10 returned to normal levels starting from 4 hr post KA to
1, 3, 5 and 15 days but showed a significant decrease at 30 days post KA treatment
compared to their untreated controls and KA treated Wt mice. However, the Wt mice
showed significantly lower levels of hippocampal IL-10 starting from 4 hr post KA
to 1, 3, 5, 15 and 30 days compared to their respective untreated controls (Figure 15).
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Figure 15: Hippocampal IL-10 levels in Wt and TNF-α Ko mice before and after KA
treatment
Data represent the Mean ± SEM, (n = 9-14), Vehicle = Distilled Water
** Significant from Wt Control at P<0.01, *** Significant from Wt Control at P<0.001,
# Significant from Ko Control at P<0.05, ### Significant from Ko Control at P<0.001,
$$$ Significant from respective Wt KA treated at P<0.001.
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3.4

Oxidative Stress Markers in Hippocampus
Oxidative stress markers were measured in the hippocampal supernatants of

control untreated, water treated and KA treated TNF-α Ko and Wt mice at different
time points (0.5 hr, 4 hr, 1, 3, 5, 15 and 30 days). These markers include:
Malondialdehyde (MDA), glutathione (GSH), Catalase (CAT), superoxide dismutase
(SOD) and nitric oxide (NO). Water treated Wt and TNF-α Ko mice showed
comparable values to those of control untreated mice.

3.4.1

Malondialdehyde (MDA)
Lipid peroxidation is used as an indicator of oxidative stress in cells and

malondialdehyde (MDA) is a naturally occurring product of lipid peroxidation. KA
treatment resulted in production of reactive oxygen species and oxidative stress. Both
KA treated TNF-α Ko and Wt mice showed elevated hippocampal MDA levels at all
time points compared to their respective untreated controls. However, KA treated
TNF-α Ko mice showed significantly high MDA levels 1 day post KA compared to
the respective KA treated Wt mice indicating more oxidative stress in TNF-α Ko
mice at this time point (Figure 16).

3.4.2

Nitric Oxide (NO)
Wt mice showed significantly higher levels of NO at 0.5 and 4 hr following

KA administration. TNF-α Ko mice exhibited significantly increased production of
NO at 0.5 hr post KA, reaching its peak value 4 hr post KA and remaining
significantly elevated at 1, 3 and 5 days and returned to normal levels at 15 and 30
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days post KA compared with their untreated controls and respective KA treated Wt
mice (Figure 17).
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Figure 16: Hippocampal MDA levels in Wt and TNF-α Ko mice before and after KA
treatment
Data represent the Mean ± SEM, (n = 9-14), Vehicle = Distilled Water
* Significant from Wt Control at P<0.05, ** Significant from Wt Control at P<0.01, ***
Significant from Wt Control at P<0.001, ## Significant from Ko Control at P<0.01, ###
Significant from Ko Control at P<0.001, $$ Significant from respective Wt KA treated
at P<0.01.
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Figure 17: Hippocampal Nitric Oxide levels in Wt and TNF-α Ko mice before and
after KA treatment
Data represent the Mean ± SEM, (n = 9-14), Vehicle = Distilled Water
* Significant from Wt Control at P<0.05, ** Significant from Wt Control at P<0.01, ***
Significant from Wt Control at P<0.001, ## Significant from Ko Control at P<0.01, ###
Significant from Ko Control at P<0.001, $ Significant from respective Wt KA treated at
P<0.05, $$ Significant from respective Wt KA treated at P<0.01, $$$ Significant from
respective Wt KA treated at P<0.001.

3.4.3

Glutathione (GSH)
Glutathione (GSH) is one of the defensive mechanisms against oxidative

stress. The basal levels of hippocampal GSH were significantly higher in control and
water treated TNF-α Ko mice compared to control and water treated Wt mice. At 1
and 3 days after KA administration, Wt mice showed significantly elevated
hippocampal GSH levels compared to their untreated controls. This elevation in GSH
levels represented a defensive mechanism against increased oxidative stress, but it
did not persist for more than 3 days after which the GSH levels declined significantly
and were nearly depleted at 5, 15 and 30 days post KA. On the other hand, TNF-α
Ko mice did not show elevation of hippocampal GSH levels post KA treatment.
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Hippocampal GSH levels in TNF-α Ko mice were significantly reduced starting from
0.5 hr to 4 hr and 1 day post KA. It was further reduced significantly and nearly
depleted at 3, 5, 15 and 30 days post KA (Figure 18).
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Figure 18: Hippocampal GSH levels in Wt and TNF-α Ko mice before and after KA
treatment
Data represent the Mean ± SEM, (n = 9-14), Vehicle = Distilled Water
** Significant from Wt Control at P<0.01, *** Significant from Wt Control at P<0.001,
# Significant from Ko Control at P<0.05, ### Significant from Ko Control at P<0.001,
$$ Significant from respective Wt KA treated at P<0.01, $$$ Significant from
respective Wt KA treated at P<0.001.

3.4.4

Catalase (CAT)
Catalase (CAT) is an antioxidant enzyme that is present in most cells as one

of the defensive mechanisms against oxidative stress. The basal activity of
hippocampal CAT were significantly higher in control and water treated TNF-α Ko
mice compared to control and water treated Wt mice. In KA treated Wt mice,
hippocampal CAT activity were significantly elevated only at 5 days post KA
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treatment compared to their untreated controls. TNF-α Ko mice showed a significant
initial decrease at 0.5 and 4 hr post KA treatment followed by a significant increase
at 1, 3 and 5 days post KA treatment compared to their untreated controls and
respective KA treated Wt mice, possibly as a defensive effort against oxidative
stress. Finally, hippocampal CAT activity significantly declined again 30 days post
KA compared to their untreated controls and respective KA treated Wt mice (Figure
19)
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Figure 19: Hippocampal Catalase Activity in Wt and TNF-α Ko mice before and
after KA treatment
Data represent the Mean ± SEM, (n = 9-14), Vehicle = Distilled Water
* Significant from Wt Control at P<0.05, # Significant from Ko Control at P<0.05, ##
Significant from Ko Control at P<0.01, ### Significant from Ko Control at P<0.001, $
Significant from respective Wt KA treated at P<0.05, $$$ Significant from respective
Wt KA treated at P<0.001.
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3.4.5

Superoxide Dismutase (SOD)
Superoxide dismutase (SOD) is an antioxidant enzyme that is present in most

cells as one of the defensive mechanisms against oxidative stress. KA treated Wt
mice showed significantly higher hippocampal SOD activity 4 hr and 1 day post KA
treatment compared to their untreated controls, while TNF-α Ko mice showed
significantly higher hippocampal SOD activity at 0.5 hr, 3 days and 30 days post KA
treatment compared to their untreated controls (3 and 30 days) and respective KA
treated Wt mice (0.5 hr, 3 and 30 days) (Figure 20).
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Figure 20: Hippocampal SOD levels in Wt and TNF-α Ko mice before and after KA
treatment
Data represent the Mean ± SEM, (n = 9-14), Vehicle = Distilled Water
* Significant from Wt Control at P<0.05, ** Significant from Wt Control at P<0.01, #
Significant from Ko Control at P<0.05, ## Significant from Ko Control at P<0.01, $
Significant from respective Wt KA treated at P<0.05, $$$ Significant from respective
Wt KA treated at P<0.001.
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3.5

Hippocampal Growth Factors
β-NGF and IGF-I were measured in the hippocampal supernatants of control

untreated, water treated and KA treated TNF-α Ko and Wt mice at different time
points (0.5 hr, 4 hr, 1, 3, 5, 15 and 30 days). Water treated Wt and TNF-α Ko mice
showed comparable values to those of control untreated mice.

3.5.1

Nerve Growth Factor (β-NGF)
-NGF is involved in the maintenance of the sympathetic and sensory

nervous systems. KA treated Wt mice did not show any changes in the levels of
hippocampal β-NGF at all time points, while TNF-α Ko mice showed a significant
elevation in hippocampal β-NGF levels at 0.5 hr, 4 hr and 1 day after which it
returned to normal levels at 3, 5, 15 and 30 days post KA treatment (Figure 21).

3.5.2

Insulin-like Growth Factor (IGF-I)
Insulin like growth factor-I (IGF-I) is a mediator of growth hormone actions

and it has been shown to be an important regulator of cell metabolism,
differentiation, and survival. The basal levels of hippocampal IGF-I were
significantly lower in control and water treated TNF-α Ko mice compared to control
and water treated Wt mice. Upon exposure to KA, the hippocampal IGF-I levels of
the TNF-α Ko mice were significantly reduced starting at 0.5 hr compared to their
untreated controls and/or respective KA treated Wt mice, then IGF-I levels returned
to normal levels at 1 day and 3 days post KA before declining again at 5, 15 and 30
days post KA. On the other hand, KA treated Wt mice showed a transient significant
decrease in hippocampal levels of IGF-I starting within 4 hr post KA treatment

65
which returned to normal levels at 1 day post KA. Moreover, the levels of IGF-I
were significantly reduced at 3, 5, 15 and 30 days post KA but not as much reduced
as in TNF-α Ko mice (Figure 22).
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Figure 21: Hippocampal β-NGF levels in Wt and TNF-α Ko mice before and after
KA treatment
Data represent the Mean ± SEM, (n = 9-14), Vehicle = Distilled Water
# Significant from Ko Control at P<0.05, $ Significant from respective Wt KA treated
at P<0.05, $$ Significant from respective Wt KA treated at P<0.01.
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Figure 22: Hippocampal IGF-I levels in Wt and TNF-α Ko mice before and after KA
treatment
Data represent the Mean ± SEM, (n = 9-14), Vehicle = Distilled Water
* Significant from Wt Control at P<0.05, ** Significant from Wt Control at P<0.01, ***
Significant from Wt Control at P<0.001, ## Significant from Ko Control at P<0.01, ###
Significant from Ko Control at P<0.001, $ Significant from respective Wt KA treated at
P<0.05, $$ Significant from respective Wt KA treated at P<0.01, $$$ Significant from
respective Wt KA treated at P<0.001.

3.6

Immunohistochemistry
Hippocampal neurodegeneration, microglial activation and astrogliosis were

all examined in the hippocampi of control untreated, water treated and KA treated
TNF-α Ko and Wt mice at different time points (0.5 hr, 4 hr, 1, 3, 5, 15 and 30 days)
by immunohistochemistry. Water treated Wt and TNF-α Ko mice showed
comparable results to those of control untreated mice. Figure 23 shows a coronal
section of mouse brain indicating different areas of the hippocampus (CA = Cornu
Ammonis).
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Figure 23: Coronal section of mouse brain showing different areas of the
hippocampus

3.6.1

Hippocampal Neurodegeneration
Hippocampal neurodegeneration was observed by FJB staining and loss of

NeuN positive cells in order to detect the time at which neurons started to die, the
affected areas in the hippocampus and the extent of neurodegeneration. Using FJB
staining, few degenerating neurons were observed as early as 1 day post KA in TNFα Ko mice. Three days after KA administration, selective hippocampal
neurodegeneration was observed in the CA3 area of KA treated TNF-α Ko mice. In
this group, neurodegeneration was also found in the CA1 regions of some of the
mice. In comparison, Wt mice showed mild neurodegeneration only in CA3 area
(Figure 24). Figure 25 showed representative images for neurodegeneration in the
hippocampus 5 days after KA treatment using NeuN staining. Following
hippocampal neurodegeneration at different time points, it was found that more
neurons were lost with time and the neuronal loss was more significant in KA treated
TNF-α Ko mice compared to KA treated Wt mice as demonstrated by obvious
disruption in the neuronal cell layers, decreased number and/or loss of NeuN positive
cells (Figure 26) and (Figure 27). Almost 95% of TNF-α Ko mice showed CA3
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lesion with variable degrees of neuronal loss, while 75% of Wt mice showed CA3
lesions. CA1 lesions were observed only in 54% of TNF-α Ko mice, and it is usually
accompanied with CA3 lesion. Rarely, some Ko mice showed only CA1 lesion.
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Figure 24: Selective hippocampal neurodegeneration (FJB staining) in Wt and TNFα Ko mice before and 3 days after KA treatment
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Figure 25: Selective hippocampal neurodegeneration (loss of NeuN positive cells) in
Wt and TNF-α Ko mice before and 5 days after KA treatment
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Figure 26: Hippocampal neurodegeneration in CA3 area (loss of NeuN positive cells)
in Wt and TNF-α Ko mice before and after KA treatment
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Figure 27: Semi-quantitative counting of hippocampal neurons in the CA3 area
(NeuN positive cells) in Wt and TNF-α Ko mice before and after KA
treatment
Data represent the Mean ± SEM, (n = 7-9), Vehicle = Distilled Water
* Significant from Wt Control at P<0.05, *** Significant from Wt Control at P<0.001,
## Significant from Ko Control at P<0.01, ### Significant from Ko Control at P<0.001,
$ Significant from respective Wt KA treated at P<0.05, $$ Significant from respective
Wt KA treated at P<0.01.

3.6.2

Microglial activation
Microglial activation (Iba-1 positive cells) was investigated at all time points

after KA treatment by immunohistochemistry. Microglia were activated earlier in
KA treated TNF-α Ko mice (0.5 hr and 4 hr post KA) compared to KA treated Wt
mice. With time, the intensities of the activated microglia increased gradually in both
TNF-α Ko and Wt mice, however the intensities of the activated microglia of KA
treated TNF-α Ko mice were significantly greater than the intensities of KA treated
Wt mice at all time points. At the late time points of 15 and 30 days post KA,
clusters of microglia were found surrounding and invading the neuronal cell layers
(Figure 28).
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Figure 28: Activated microglia clusters invading neuronal cell layers in the CA3 area
of the hippocampus of TNF-α Ko mice 30 days post KA

Microglial activation was evident in all areas of the hippocampus but with
time microglia tended to be more concentrated and localized close to areas of
neurodegeneration specifically neurons in the CA3 area. Figure 29 shows
representative images for microglia in the CA3 area of the hippocampus at different
time points for both TNF-α Ko and Wt mice. Figure 30 shows a semi-quantitative
counting of microglia in the CA3 area (Iba-1 positive cells) in hippocampi of Wt and
TNF-α Ko mice before and after KA treatment.
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Figure 29: Microglial activation (Iba-1 positive cells) in hippocampi of Wt and TNFα Ko mice before and after KA treatment
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Figure 30: Semi-quantitative counting of microglia in the CA3 area (Iba-1 positive
cells) in hippocampi of Wt and TNF-α Ko mice before and after KA
treatment
Data represent the Mean ± SEM, (n = 7-9), Vehicle = Distilled Water
* Significant from Wt Control at P<0.05, ** Significant from Wt Control at P<0.01, ***
Significant from Wt Control at P<0.001, # Significant from Ko Control at P<0.05, ##
Significant from Ko Control at P<0.01, ### Significant from Ko Control at P<0.001, $$
Significant from respective Wt KA treated at P<0.01.

3.6.3

Astrogliosis
Astrogliosis (GFAP expression) was examined at all time points after KA

treatment by immunohistochemistry. Usually, astrocytes are activated following
microglial activation. Similar to microglia, astrogliosis occurred earlier in KA treated
TNF-α Ko mice (1-3 days post KA) compared to KA treated Wt mice. With time, the
intensities of astrogliosis increased gradually in both TNF-α Ko and Wt mice,
however the intensities of astrogliosis of KA treated TNF-α Ko mice were
significantly greater than intensities of KA treated Wt mice at all time points. Like
microglia, at late time points (15 and 30 days), clusters of astrocytes were found
surrounding and invading the neuronal cell layers. Astrogliosis occurred in all areas
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of the hippocampus but with time astrocytes became more concentrated and localized
close to areas of neurodegeneration specifically neurons in the CA3 area. Figure 31
showed a representative image for the activated astrocytes invading the neuronal cell
layers in the CA3 area. Figure 32 shows representative pictures for the distribution of
activated astrocytes in the hippocampus at different time points for both TNF-α Ko
and Wt mice, with more focus on the CA3 area (Figure 33). Figure 34 shows a semiquantitative counting of astrocytes in the CA3 area (GFAP positive cells) in
hippocampi of Wt and TNF-α Ko mice before and after KA treatment.

Figure 31: Activated astrocytes invading neuronal cell layers in the CA3 area of the
hippocampus of TNF-α Ko mice 5 days post KA
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Figure 32: Astrogliosis (GFAP positive cells) in hippocampi of Wt and TNF-α Ko
mice before and after KA treatment (Magnification 5x)
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Figure 33: Astrogliosis (GFAP positive cells) in hippocampi of Wt and TNF-α Ko
mice before and after KA treatment (Magnification, 10x)
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Figure 34: Semi-quantitative counting of astrocytes in the CA3 area (GFAP positive
cells) in hippocampi of Wt and TNF-α Ko mice before and after KA
treatment
Data represent the Mean ± SEM, (n = 7-9), Vehicle = Distilled Water
** Significant from Wt Control at P<0.01, *** Significant from Wt Control at P<0.001,
### Significant from Ko Control at P<0.001, $ Significant from respective Wt KA
treated at P<0.05, $$ Significant from respective Wt KA treated at P<0.01.
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3.7

Hippocampal Levels of NFκB and AKT
To better understand the mechanism behind the increased neurodegeneration

in TNF-α Ko mice, a short term study was conducted and we employed Western
blotting to examine NFκB and AKT expression at 1 and 5 days post KA treatment.
Both NFκB and AKT expression was detectable by Western blotting in hippocampal
supernatants among all groups of mice with or without KA treatment. There was no
difference in AKT expression among all groups of mice. Five days after KA
treatment, TNF-α Ko mice showed significantly higher NFκB expression than Wt
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mice (Figure 35).
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Figure 35: NFκB and AKT expression in hippocampi after KA treatment detected by
Western blotting.
Data represent the Mean ± SEM, (n = 9-14), Vehicle = Distilled Water
# Significant from Ko Control at P<0.05, $ Significant from respective Wt KA treated
at P<0.05.
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To further confirm our finding from Western Blotting, we also measured the
NFκB production at 1 and 5 days post KA treatment by ELISA. The results
confirmed that there was a significant increase in KA-induced NFκB expression in
hippocampi of TNF-α Ko mice five days after KA treatment. There was no
difference between the two groups of mice one day after KA treatment (Figure 36).
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Figure 36: NFκB production in hippocampi after KA treatment measured by ELISA.
Data represent the Mean ± SEM, (n = 9-14), Vehicle = Distilled Water
# Significant from Ko Control at P<0.05, $$ Significant from respective Wt KA treated
at P<0.01.
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Chapter 4: Discussion
Neurodegeneration is a common feature of a large number of diseases that
come under the umbrella of “neurodegenerative diseases”; and involve loss of nerve
structure and function. The prevalence of neurodegenerative disorders such as
Alzheimer’s disease and Parkinson’s disease is increasing, but exact mechanisms and
effective treatments are lacking. The burden of these neurodegenerative diseases is
growing, as the population ages, with huge economic and human costs (Atkinson,
2010).
The causes of neurodegenerative diseases are mostly unknown, and even
when they have been identified, the mechanisms by which the diseases start and
progress remain speculative. Multiple components are linked to the pathogenesis of
neurodegenerative diseases including protein aggregation (Rubinsztein, 2006),
mitochondrial dysfunction and oxidative stress (Lin and Beal, 2006), diet
components and neurotoxins (Brown et al., 2005), vascular disorders, excitotoxicity
(Salinska et al., 2005), and neuroinflammation (Wyss-Coray and Mucke, 2002).
In general, inflammation is a protective response to various cell and tissue
injuries to destroy and remove the detrimental agents and injured tissues, thereby
promoting tissue repair. However, when inflammation is uncontrolled, it can cause
excessive cell and tissue damage ultimately leading to destruction of normal tissue
and chronic inflammation (Fischer and Maier, 2015).
Neuroinflammation was previously considered as a passive response to
neuronal damage. However, several studies proved that inflammation may be a basic
mechanism driving the progressive nature of multiple neurodegenerative diseases
(Olmos and Llado, 2014).
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Tumor necrosis factor alpha (TNF-α) was originally identified as a factor that
leads to rapid necrosis of transplantable tumors in mice (Carswell et al., 1975) and
now it is considered as a key player in the initiation and orchestration of
inflammation and immunity. TNF-α is known as a powerful proinflammatory
cytokine with stimulatory activities for most cells of the immune system (Wajant et
al., 2003). Its role in the central nervous system (CNS) was not observed until 1987,
when microglia was found to produce TNF-α (Frei et al., 1987).

In the healthy CNS, TNF-α participates in crucial physiological processes
such as injury-mediated microglial and astrocyte activation (Merrill, 1991),
regulation of blood brain barrier permeability (Sedgwick et al., 2000), febrile
responses (Leon, 2002), glutamatergic transmission (Pickering et al., 2005), synaptic
plasticity (Santello and Volterra, 2012), learning and memory (Beste et al., 2010),
sleep (Krueger, 2008), food and water intake (Plata-Salaman, 2001), and astrocyteinduced synaptic strengthening (Santello et al., 2011). In pathological conditions,
TNF-α expression increased in the brain following acute injury (ischemia, trauma),
infection, neurodegeneration, and chemically induced neurotoxicity (Allan and
Rothwell, 2001; Viviani et al., 2004). However, other findings support a
neuroprotective role for TNF-α. In particular, knock-out mice lacking both TNF
receptors or TNFR1 receptors only (Bruce et al., 1996; Gary et al., 1998; Lu et al.,
2008) show exacerbated ischemic and excitotoxic brain damage. Thus, a controversy
exists between the neurotoxic and the neuroprotective roles of TNF-α in the CNS.

The present study was conducted to elucidate the role of TNF-α in
neurodegeneration and to follow up the sequence of events occurring in the
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neurodegenerative process. This is achieved by intranasal kainic acid (KA) treatment
to induce neurodegeneration in TNF-α Ko mice and C57BL/6 Wt mice and study the
progress of the neurodegeneration at different time points (0.5 hr, 4 hr, 1, 3, 5, 15 and
30 days) in order to have a better understanding for the neurodegenerative process in
presence and absence of TNF-α. Our results show that TNF-α Ko mice were more
susceptible to kainic acid (KA)-induced neurotoxicity, as demonstrated by more
severe seizures, changed behavior, more degenerating neurons in hippocampi, as
well as more glial activation, severe oxidative stress and NO production with
malfunctioning defensive mechanisms. Additionally, KA-treatment up-regulated the
expression of NFκB to a greater degree after 5 days in KA treated TNF-α Ko mice
when compared with KA treated Wt mice. We concluded that TNF-α deficiency
worsens KA-induced neurotoxicity and that TNF-α may play a protecting role in
KA-induced neurotoxicity via the regulation of the NFκB signaling pathway.

Neuronal excitation involving the excitatory glutamate receptors is
recognized as an important mechanism underlying neurodegeneration (Wang et al.,
2005). Excitotoxic cell death is commonly induced experimentally by the
administration of kainic acid. KA is a non-degradable analog of glutamate and 30fold more neurotoxic than glutamate. It is a potent agonist affecting the
AMPA/kainate class of glutamate receptors (Chihara et al., 2009; Wang et al., 2005).
Excitotoxic injury appears to be mediated predominantly by an excessive influx of
calcium into neurons through ionic channels (Mayer et al., 1984). Calcium entry into
neurons plays a critical role in seizure genesis (McNamara, 1992; Meyer, 1989).
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Administration of KA to rodents resulted in recurrent seizures, behavioral
changes and subsequent selective degeneration of neuronal populations in the brain
(McKhann et al., 2003; Tripathi et al., 2009). Astrogliosis and microglial activation
with subsequent cytokines and other inflammatory molecules production are the
other characteristics of KA-induced neurodegeneration.

In the present study, KA treated TNF-α Ko mice displayed rapid onset of
seizures and more severe seizures than KA treated Wt mice. This immediate and
prolonged response is considered the first indication that TNF-α Ko mice were more
sensitive to KA-induced neurotoxicity than Wt mice.

Neuronal injury is the main characteristic of KA-induced excitotoxicity. KAinduced damage seriously impacted the hippocampus, which is particularly
vulnerable to KA-induced neurotoxicity due to the high density of its kainate
receptors (Darstein et al., 2003). CA3 region has the highest abundance of kainate
receptors, the activation of which can elevate the concentration of reactive oxygen
species (ROS) and impair the normal function of mitochondria (Carriedo et al., 2000;
Lauri et al., 2001; Reynolds and Hastings, 1995). CA3 neurons are directly excited
by stimulation of their KA receptors, and indirectly by increased glutamate efflux
secondary to KA stimulation of mossy fibers. Moreover, depolarization of CA3
pyramidal cells my lead to endogenous glutamate release in the CA1 region
(Ashwood and Wheal, 1986; Kim et al., 2000). CA3 synchronization produces
spreading epileptiform activity that extends to CA1 and other limbic structures
(Bausch and McNamara, 2004; Ding et al., 1998).
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In this study, neuronal degeneration started as early as 1 day post KA
treatment in TNF-α Ko mice and continued in a progressive way up to 30 days. KA
treated C57BL/6 Wt mice showed degenerating neurons 3 days post KA in CA3
area, while KA treated TNF-α Ko mice showed degenerating neurons in both CA3
and CA1 regions. The neuronal damage was more severe and widely extended in
TNF-α Ko mice specifically at later time points (15 and 30 days post KA treatment)

CA1 pyramidal neurons receive two distinct excitatory inputs that are capable
of influencing hippocampal output, and thus involved in spatial memory and memory
consolidation (Iijima et al., 1996; Speed and Dobrunz, 2009). Damage in CA3/CA1
regions of hippocampus induced by KA mainly results in spatial learning deficits.

In our study mice were exposed to a battery of behavioral tasks before and
after KA treatment. The behavioral tests include Elevated Plus Maze (EPM) for
anxiety and exploration assessment, Open Field test for locomotion and rearing
evaluation and Y-Maze for spontaneous alternation and short term memory
assessment.

In the EPM, TNF-α Ko mice showed changed behavior (5, 15 and 30 days
post KA treatment) in the form of increased frequency and time spent in open arms,
less frequency in closed arms and increased number of feces in 5 min compared with
that of KA treated Wt mice especially at 30 days post KA treatment. At all time
points, both Wt and TNF-α Ko mice showed decreased head drops in open arms and
risk assessment behavior compared with those observed before KA treatment. This
observation reflects decreased exploration in both strains following KA treatment.
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However, TNF-α Ko mice showed significantly decreased counts of risk assessment
behavior 30 days post KA treatment compared to Wt mice, indicating attenuated
ability of risk assessment (Komada et al., 2008).

In the open-field test, both Wt and TNF-α Ko mice showed increased
locomotion and rearing counts 3, 5, 15, and 30 days post KA treatment compared
with those observed before KA treatment. TNF-α Ko mice showed significantly
more locomotion activity compared with KA treated Wt mice at 3 days and 30 days.
The highest levels recorded for locomotion and rearing counts were 3 days post KA
treatment.

In Y-Maze test, both KA treated TNF-α Ko and Wt mice showed more arm
entries at 3, 5, 15 and 30 days post KA treatment compared with those observed
before KA treatment. Similarly, the highest arm entries count was observed 3 days
post KA treatment. This increase in arm entries count is because of the hyperactivity
of KA treated mice similar to that observed in the Open Field test. On the other hand,
the percent of successful alternation between arms was decreased in both KA treated
TNF-α Ko and Wt mice at 3 and 5 days post KA treatment compared to those
observed before KA treatment. The deterioration in the successful alternation
persisted in TNF-α Ko mice at 15 and 30 days post KA treatment, while Wt mice
showed improved levels of alternation at 30 days post KA.

The summary of all behavioral studies is that KA treatment resulted in
hyperactivity and reduced risk assessment behavior in both TNF-α Ko and Wt mice.
However, this changed behavior was more prominent in TNF-α Ko mice specifically
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3 days and 30 days post KA treatment. The short term memory was affected by KA
treatment in both TNF-α Ko and Wt mice, but there is some sort of improvement
observed in Wt mice, but not in TNF-α Ko mice, specifically at 30 days post KA.

It has been shown that KA treated Wistar rats are impaired in the water maze
and object exploration tasks, while hyperactive in the open field test (Gobbo and
O'Mara, 2004; Gobbo and O'Mara, 2005). Intra-peritoneal injection of KA into the
developing rat brain induced impaired short-term spatial memory in the radial-arm
maze, deficient long-term spatial learning and retrieval in the water maze, and a
greater degree of anxiety in the elevated plus maze (Sayin et al., 2004).

The deterioration in the cognitive functions of the TNF-α Ko mice may be
due to the extensive neuronal loss in the CA3/CA1 areas of the hippocampus.
However, the possibility that the absence of TNF-α might have implication in the
deterioration of the cognitive functions cannot be ruled out. In the CNS, TNF-α was
found to affect AMPA receptor trafficking and hence, may affect synaptic plasticity
(Beattie et al., 2002). Several studies demonstrated that synaptic scaling is altered by
TNF-α and that changes in long-term potentiation (LTP), neurotransmitter
metabolism, and neuro-developmental processes are altered by TNF-α as well
(Stellwagen and Malenka, 2006). Our results are in line with a previous study
showing that continuous exposure of the brain to TNF-α, even in the adult brain, is
essential for maintenance of normal cognitive function (Beattie et al., 2002).

KA-induced excitotoxicity is accompanied by increased activation of
microglia and astrocytes. Microglia is the main effector cell type responsible for
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immune and inflammatory responses in the CNS. Following the injury, all cells
present a metabolic reprogramming to cover the bioenergetic and substrate demand
for the trophic/inflammatory processes to take place (Gimeno-Bayon et al., 2014)
with the coexistence of various factors. Microglia show a range of phenotypes
ranging from the well known proinflammatory activation state to a trophic one
involved in cell repair and extracellular matrix remodeling (Domercq et al., 2013).
The normal role of microglia could be partly connected to neuroprotection, whereas
in pathological conditions microglia may become disease-promoting cells. In KAinduced hippocampal injury, microglial activation is generally believed to contribute
to neuroinflammation and neurodegeneration. Astrocytes have functional receptors
for the excitatory neurotransmitter, glutamate, and respond to physiological
concentrations of this substance with oscillations in intracellular Ca2+ concentrations
and spatially propagating Ca2+ signals. Astrogliosis induced by excitotoxicity has
been considered as a marker for neurotoxicity (Batlle et al., 2015).

In the present study, TNF-α deficiency enhanced KA-induced microglial
activation in the hippocampus. More activated microglial cells have been shown in
KA treated TNF-α Ko mice 0.5 hr to 4 hr post KA treatment compared to KA treated
Wt mice. At later time points post KA treatment, the number and intensity of Iba-1
positive cells in the hippocampus increased significantly in TNF-α Ko mice. Three
days post KA is the peak point at which microglial activation is observed covering
all hippocampal areas. At later time points, activated microglia clustered surrounding
and within degenerating neurons, specifically neurons in the CA3 area.
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In vitro studies showed that microglial activation was detected following
treatment of cultures with pathogenic factors when neither neuronal nor astroglial
morphological changes could be observed (Figiel and Dzwonek, 2007). Comparative
studies carried out on animals treated with neurotoxic doses of TMT revealed that
microglial activation precedes the astrocytic reaction and neuronal death (McCann et
al., 1996).

Microglial activation was initially considered as a transient event (Streit et al.,
1988), however, in this study we have seen that microglial activation persisted up to
30 days which was the latest time point in our study and it may persist for more than
this as well. Reports have shown that microglia can remain chronically activated
(Huh et al., 2003; McGeer et al., 2003) in a process termed reactive microgliosis.
Reactive microgliosis involves microglial activation that occurs in response to
neuronal damage, which is then continues and persists by further microglial
activation and neurotoxicity. It was found that chronic microglial activation can
continue years after MPTP exposure in humans (Langston et al., 1999) and primates
(McGeer et al., 2003) despite the fact that the exposure to MPTP was brief.

It is known that microglial activation stimulated activation and proliferation
of astrocytes (Batlle et al., 2015). In the present study, astrogliosis occurred earlier in
KA treated TNF-α Ko mice (1-3 days post KA) compared to KA treated Wt mice.
Similarly, three days post KA is the peak point at which astrogliosis is observed
covering all hippocampal areas in KA treated TNF-α Ko mice. At later time points,
the intensities of astrogliosis increased gradually and clusters of astrocytes were
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found surrounding and invading the degenerating neurons, specifically neurons in the
CA3 area.

Oxidative stress is a common characteristic shared across numerous
neurodegenerative diseases (Perluigi et al., 2005). ROS play a dual role in
determining cell fate. Low levels of ROS may function as second messengers
activating pathways that protect cells against apoptotic stimuli. On the other hand,
excess ROS are associated with cell death, and blocking ROS often prevents cell
death (Chandra et al., 2000). The brain is especially vulnerable to oxidative stress
because of its high consumption of oxygen and low levels of endogenous
antioxidants (Margaill et al., 2005; Schreibelt et al., 2007). At the cellular level, ROS
and RNS can cause DNA and protein oxidation as well as lipid peroxidation. The
latter is particularly relevant in the CNS due to the high amount of polyunsaturated
fatty acids. ROS also may initiate cell death processes through affecting various
signaling cascades (Morgan et al., 2007).

The production of ROS in microglia is derived from multiple sources, such as
peroxidases inside the cell, NADPH oxidase on the membrane surface, or the
oxidative processes of mitochondria (Circu and Aw, 2009). However, NADPH
oxidase is the predominant source of microglial extracellular ROS production (Gao
et al., 2002; Qin et al., 2004). It is a membrane-bound enzyme that is dormant in
resting phagocytes and can be activated upon exposure to specific stimuli, such as
environmental factors (LPS, rotenone, paraquat), endogenous protein toxins (βamyloid peptide, α-synuclein), and neuronal injury (Babior, 2000). NADPH oxidase
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is upregulated in neurodegenerative diseases such as PD (Wu et al., 2003) and
Alzheimer’s disease (Block, 2008).

Interestingly, microglial ROS production is consistent upon microglial
activation, while the production of other factors such as NO, TNF-α or Prostaglandin
E2 from microglia is much less consistent across a diverse list of toxins (Block et al.,
2004; Gao et al., 2002; Qin et al., 2004). This indicates that microglial-derived ROS
may be an essential and common factor of microglial activation.

The activation of KA receptors produces membrane depolarization and
results in alteration in intracellular calcium concentrations, which is required to
trigger the neuronal death cascade (Brorson et al., 1994). KA administration
increased the generation of ROS and RNS. KA stimulated the release of lactate
dehydrogenase, an indicator for loss of cell membrane integrity, suggesting that KA
induced damage to mitochondrial function. KA also induced mitochondrial loss of
glutathione homeostasis and decreased Mn-SOD protein expression. There is
growing evidence that free radical generation plays a key role in the neuronal
damage (Jones et al., 2002).

The present study showed that KA treatment resulted in a significant
oxidative stress at all time points in both TNF-α Ko and Wt mice. This oxidative
stress was represented by increased levels of lipid peroxidation products such as
MDA, increased NO production, stimulation of antioxidant defensive mechanisms
(CAT and SOD), and reactive oxygen species dependent glutathione (GSH)
depletion.
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Both KA treated TNF-α Ko and Wt mice showed elevated hippocampal
MDA levels at all time points compared to their respective untreated controls.
However, the oxidative stress in KA treated TNF-α Ko mice started earlier and was
significantly higher compared to the respective KA treated Wt mice. Our results
showed that ROS production is the very early event occurring as early as 0.5 hr post
KA treatment with a peak at 1 day post KA. A previous study showed that the peak
of ROS/RNS production occurs 4 hrs after stimulation of the dopaminergic cell
culture with LPS (Gao et al., 2002; Harms et al., 2012).

Nitric oxide (NO) is involved in many physiological and pathological
processes within the CNS. It can be formed enzymatically from L-arginine by
inducible NO synthase (iNOS) in microglia and to some extent also in astrocytes
(Wiesinger, 2001). iNOS is scarcely expressed in the brain but it is induced during
gliosis in pathological situations including AD (Aliev et al., 2009) and PD (Dawson
and Dawson, 1998). ROS, specifically superoxide, can interact with NO to produce
peroxynitrite, which has been shown to be very reactive and toxic to neuronal cells
(Szabo et al., 2007). Inflammatory mediators, including LPS and some cytokines
(TNF-α, IL-1β, and IFN-γ) induce the transcriptional activation of the iNOS gene in
astrocytes and microglia via activation of the transcription factors STAT1 and NF-κB
(Grzybicki et al., 1996; Hewett and Hewett, 2012; Possel et al., 2000). These factors
translocate to the nucleus and bind to response elements present in the iNOS coding
sequence. Elevated production of NO by increased activity of iNOS is thought to
participate in KA-induced neurotoxicity (Urrutia et al., 2014).
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In the present study, we observed that KA is capable of increasing
hippocampal NO production in TNF-α Ko and Wt mice. However, TNF-α Ko mice
showed earlier (at 0.5 and 4 hr post KA) and significantly higher NO production at 1,
3 and 5 days post KA treatment compared to their respective KA treated Wt mice.

The NO donor, sodium nitroprausside, was found to cause significant
neuronal death and demyelination when infused into the brains of mice (Blais and
Rivest, 2004). The neurodegeneration caused by sodium nitroprausside is
accompanied by microglial activation and the induction of the proinflammatory
cytokines such as TNF-α and IL-1β. Animals deficient in TNF-α showed dramatic
exacerbation of the sodium nitroprausside induced damage to neurons. The absence
of TNF-α resulted in an exaggerated response by microglia. These results proved that
early endogenous TNF-α release after the sodium nitroprausside insult is
neuroprotective, and demonstrated that microglia of the brain can still be activated in
the absence of this important proinflammatory cytokine (Turrin and Rivest, 2006).

Our results are in agreement with previous studies highlighting the
neuroprotective effect of TNF-α. One study showed that mice lacking TNF receptors
exhibited increased oxidative stress and striatal lesion size following 3-nitropropionic
acid (3-NP) administration (Bruce-Keller et al., 1999). Other studies on hippocampal
and cortical cell cultures enriched in neurons have shown that TNF-α can protect
neurons against oxidative stress and the cytotoxic effects of glutamate and β-amyloid
(Furukawa and Mattson, 1998; Mattson, 1997).
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As our results showed enhanced oxidative stress following KA treatment, we
aimed to check the status of the endogenous antioxidant defensive mechanisms.
Glutathione, catalase and superoxide dismutase are the three most important defense
mechanisms because the body can produce more of them as needed when certain free
radicals are present. Glutathione is the most abundant endogenous antioxidant.

Our results showed that the basal levels of hippocampal GSH were
significantly higher in TNF-α Ko mice compared Wt mice. After KA treatment and
as a response to the developed oxidative stress, Wt mice showed significantly
elevated hippocampal GSH levels as a defensive mechanism. This response was
transient and after 3 days of KA treatment, GSH levels declined and nearly depleted
at 5, 15 and 30 days post KA. On the other hand, TNF-α Ko mice did not show the
transient elevation of hippocampal GSH levels at all. Hippocampal GSH levels in
TNF-α Ko mice were significantly reduced gradually 0.5 hr, 4 hr, 1, 3 and 5 days
post KA. It was further reduced and nearly depleted 15 and 30 days post KA. These
results suggested that GSH defensive mechanism is malfunctioning in TNF-α Ko
mice compared to Wt mice.

Similar to GSH, the basal activity of hippocampal CAT were significantly
higher in TNF-α Ko mice compared to Wt mice. CAT activity, as a defensive
mechanism, was significantly low at 0.5 and 4 hr and was activated at 1 day post KA
in TNF-α KO mice in response to their higher oxidative stress and persisted for up to
5 days post KA. Hippocampal CAT activity was then significantly reduced again 30
days post KA compared to their untreated controls and respective KA treated Wt
mice. These results showed attempts from the TNF-α Ko mice to antagonize the
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emerging oxidative stress. However, these attempts worked well in the early stages
but failed to persist more than 5 days post KA treatment.

Higher hippocampal SOD activity were observed in KA treated Wt mice 4 hr
and 1 day post KA treatment. This early response was not observed in TNF-α Ko
mice that showed significantly higher hippocampal SOD activity only at 3 days and
30 days post KA treatment compared to their untreated controls. These time points
represent the critical points in the process of KA-induced neurotoxicity for TNF-α
Ko mice. At three days post KA treatment, severe gliosis and significant neuronal
death became evident and at 30 days post KA treatment severe neuronal loss was
observed in TNF-α Ko mice compared to their respective KA treated Wt mice. At
these critical time points the TNF-α Ko mice tried to antagonize the increasing
oxidative stress without any success.

It has been documented that prior exposure to a sub-lethal dose of TNF-α
makes cells resistant to a subsequent TNF-α challenge. The mechanism by which this
TNF-α mediated cellular resistance occurs is related to the enhancement of the
intracellular antioxidant capacity (Zimmerman et al., 1989). Examples of this are
increased activity of mitochondrial manganese superoxide dismutase (Wong and
Goeddel, 1988), and other protective proteins, such as Bcl-2-related family member
A1 (Karsan et al., 1996). The molecular basis of the TNF-α induced cellular
tolerance is not fully understood at present. One possible mechanism may involve
TNF-α induced generation of ROS by leakage from the mitochondrial electron
transport chain (Schulze-Osthoff et al., 1992). These intracellular ROS could
promote rapid induction of intracellular GSH synthesis (Shi et al., 1994). An

96
interesting study showed that brief exposure to TNF-α caused a transient depletion of
GSH. However, prolonged exposure to TNF-α was found to increase GSH levels
(Rahman et al., 1999; Rahman et al., 1996). Elevation of GSH levels has also been
observed in cultured rat hepatocytes following treatment with TNF-α, which
protected the cells against the cytotoxic effects of further oxidant stresses (Imanishi
et al., 1997).

Several studies highlighted the neuroprotective effects of TNF-α in different
experimental animal models of neuronal injury such as ischemic tolerance
(Nawashiro et al., 1997; Zimmermann et al., 2001) and glucose deprivation-induced
injury, and these effects seem to involve attenuation of the elevation of intracellular
Ca2+ (Cheng et al., 1994). Other potential mechanisms of TNF-α mediated
neuroprotection include stimulation of antioxidant pathways (Wilde et al., 2000).
Induction of the mitochondrial antioxidant enzyme Mn-SOD by TNF-α has been
reported in a wide variety of cell types and has been assumed to function as a central
protective mechanism against TNF-α induced apoptosis (Barger et al., 1995; Cheng
et al., 1994; Mattson et al., 1997).

Based on the previous findings, it is clear that deficiency of TNF-α renders
the body more susceptible to oxidative stress. May be as a compensation, the basal
levels of GSH and CAT were higher in TNF-α Ko mice compared to Wt mice.
Although GSH levels were higher initially in TNF-α Ko mice, lack of TNF-α makes
GSH a malfunctioning antioxidant in these mice. The exact mechanism by which
TNF-α regulates GSH still need to be studied.
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Some peripheral studies showed an inverse relation between TNF-α and
Catalase. For example in a study on cardiomyocyte hypertrophy, it was found that
TNF-α as a hypertrophic stimulus can downregulate catalase (Murtaza et al., 2008).
In another study, the hepatic catalase expression was also significantly decreased in
after TNF-α treatment (Beier et al., 1992). Indeed, in livers of rats treated for 5 days
with TNF, catalase activity was reported to be significantly decreased (Yasmineh et
al., 1991). In agreement with the latter reports, our finding of elevated hippocampal
catalase levels in TNF-α Ko mice could be, in addition to increased oxidative stress,
due to the absence of TNF-α in these mice.

Neurodegeneration is associated with increased inflammatory mediators in
the CNS such as in AD, MS… etc (Bennett and Stuve, 2009; Rojo et al., 2008). A
large number of inflammatory mediators including NO, TNF-α, IL-6, IL-1β, IL-12,
IL-18, TGF-β and IL-10 are released by activated microglia and astrocytes after KA
treatment (Zheng et al., 2011). Altered expression of cytokines in response to brain
injury has diverse actions that can exacerbate, mediate, reduce or inhibit neuronal
damage and influence the disease development (Colton and Wilcock, 2010; Kato and
Walz, 2000; Kerschensteiner et al., 2009). Results from studies using KA model also
indicated that cytokines are involved in neuron-glia intercommunication and
manipulation of pro- and anti-inflammatory cytokines can modify the outcome with
regard to the seizure activity, behavioral changes as well as the neuropathological
consequences (Chen et al., 2004; De Sarro et al., 2004; Swanson, 2009).

IL-1β is a proinflammatory cytokine produced in abundance by activated
microglia. Accumulating evidence in experimental neurodegenerative models
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indicates that IL-1β is pivotal in the excitotoxicity leading to neuronal death (Liu and
Hong, 2003). Primary cultured microglia are significantly activated by KA with
increased IL-1β levels and IL-1β can mediate KA-induced excitotoxic injuries to
hippocampal neurons in vitro and in vivo (Zheng et al., 2009). On the other hand, IL6 was found to bear both pro- and anti-inflammatory functions. It appeared to be a
critical factor in early phases of CNS insults, taking part in the orchestration of
attempts for tissue repair (Amor et al., 2010). IL-6 mRNA was increased in the
hippocampus, cortex, amygdale, and meninges, and IL-6 receptor was upregulated in
the hippocampus in the rat brain after KA-induced status epilepticus (Lehtimaki et
al., 2003).

In the present study, only KA treated Wt mice showed initial elevation of
hippocampal TNF-α levels starting from 0.5 hr till 5 days post KA treatment. Both
KA treated TNF-α Ko and Wt mice exhibited an initial increase in the levels of
hippocampal IL-6 and IL-1β at 0.5 and 4 hr post KA treatment compared to their
respective untreated controls. During this period, most of the mice exhibited seizures.
Later on, the hippocampal IL-6and IL-1β levels declined.

IL-12 was found to be produced by activated microglia in response to KA,
and IL-12 deficiency may alleviate hippocampal injury upon KA challenge,
indicating a critical role of IL-12 in excitotoxin-induced brain injury (Chen et al.,
2004). Moreover, expression IL-12 was increased in IL-18 deficient mice as
compared with controls in association with increased microglial activation,
suggesting that the null role of IL-18 in excitotoxic injury may be compensated by
the upregulated levels of IL-12 (Zhang et al., 2007). In the present study, the levels
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of hippocampal IL-12 was elevated 0.5 and 4 hr post KA treatment in KA treated
TNF-α Ko and Wt mice compared to the respective untreated controls. This increase
is followed by a sharp decrease that happened earlier in TNF-α Ko mice (1 day post
KA) compared to Wt mice (3 days post KA). At 5, 15 and 30 days post KA; the
levels of IL-12 in Wt mice were comparable or less than the normal levels. While the
IL-12 levels in TNF-α Ko mice returned to their normal levels at 3 and 5 days post
KA treatment, then became significantly lower than their respective untreated
controls and KA treated Wt mice.

IL-10 is an anti-inflammatory cytokine that suppresses proinflammatory
cytokines production such as IL-1β and TNF-α and iNOS, in cell cultures (Aloisi,
1999; Ledeboer et al., 2000). It also represses expression of MHC and co-stimulatory
molecules, and inhibits their antigen presenting functions (Sabat, 2010). The main
function of IL-10 in inflammatory and autoimmune conditions is the limitation and
termination of inflammatory response and regulation of differentiation and
proliferation of immune cells (Bashyam, 2007; Park et al., 2007). IL-10 is therefore
considered to be an important anti-inflammatory modulator of glial activation,
functioning to maintain a balance between pro- and anti-inflammatory cytokine
levels in the CNS (Sawada et al., 1999).

The results of the present study showed that the basal levels of hippocampal
IL-10 were significantly lower in control and water treated TNF-α Ko mice
compared to control and water treated Wt mice. This observation may indicate that
TNF-α Ko mice are less protected against neuroinflammation than Wt mice. Half an
hour post KA treatment, TNF-α Ko mice showed a transient elevation in the levels of

100
hippocampal IL-10, then returned back to normal levels followed by a significant
decrease at 30 days post KA treatment compared to their untreated controls and KA
treated Wt mice. KA treated Wt mice showed decreasing levels of hippocampal IL10 starting from 4 hr post KA to 1, 3, 5, 15 and 30 days compared to their respective
untreated controls.

The overall results of hippocampal cytokine levels indicate an early stage of
neuroinflammation occurring immediately within 0.5 – 4 hr post KA treatment. This
neuroinflammation is characterized by elevation of proinflammatory cytokines (IL-6,
IL-1β and IL-12) and reduction of anti-inflammatory cytokines (IL-10). These
findings are in line with the fact that activated microglia, the main producer of these
cytokines, were observed in the hippocampus as early as 0.5 hr post KA treatment.
We found that neuroinflammation is occurring before neuronal cell death and this
finding add more evidence that neuroinflammation is not a passive response to
neuronal injury but it can actively participate in the process of neurodegeneration.
The alterations in the levels of cytokines starting from 1 day post KA in both TNF-α
Ko and Wt mice may represent changes in the phenotype of microglial activation
between M1 and M2 microglia.

We observed that both TNF-α Ko and Wt mice exhibit more or less similar
pattern of elevation or reduction of cytokine production. However, in a previous
study, they showed significantly lower levels of different cytokines (IL-1β, IL-6, IL10, IL-12) produced from TNF-null microglia upon stimulation with LPS compared
to wild type microglia. They concluded that TNF-α is critical for expression and/or
secretion of a number of cytokines and chemokines in brain microglia (Douni et al.,
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1995; Harms et al., 2012). The rationale behind these opposite results may be
because they were running in vitro model and we are using in vivo model. They also
used different source for microglial activation which is LPS and we used KA, and
these differences can affect the outcome of the experiment.

Several trophic factors were found to be produced in case of brain injury as a
compensatory mechanism. β-NGF is involved in maintaining survival and promoting
plasticity of neurons in the CNS (Chen and Swanson, 2003). Our results showed that
KA treated Wt mice did not show any changes in the levels of hippocampal β-NGF
at all time points, while TNF-α Ko mice showed a remarkable elevation in
hippocampal β-NGF levels at 0.5 hr, 4 hr and 1 day post KA treatment after which it
returned to its normal levels. This elevation in β-NGF may represent a protective
mechanism to prevent the greater neuronal damage observed in TNF-α Ko mice.

It was found that microglia expressed β-NGF and that activation of microglia
with LPS further increased the expression of β-NGF (Barouch et al., 2001). Recent
evidence indicates that cytokines are potent inducers of β-NGF expression both in
peripheral tissues and the CNS and that β-NGF, in addition to its neurotrophic action,
also acts as an immune-regulatory agent (Steiner et al., 1991).

Insulin like growth factor-I (IGF-I) is a mediator of growth hormone actions
and it has been shown to be an important regulator of cell metabolism,
differentiation, and survival. Its neuroprotective potential has been documented in
ischemia (Guan et al., 2003), traumatic brain injury (Kazanis et al., 2003), or stroke
(Liu et al., 2004), as well as in a number of animal models of neurodegenerative
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diseases such as amyotrophic lateral sclerosis (Kaspar et al., 2003), multiple sclerosis
(Chesik et al., 2007), Alzheimer's (Torres-Aleman, 2007) and Parkinson's disease
(Ebert et al., 2008). Moreover, it is reported that IGF-I is able to ameliorate
hippocampal neurodegeneration and protect against cognitive deficits temporal lobe
epilepsy (Miltiadous et al., 2011).

Our results showed that the basal levels of hippocampal IGF-I were
significantly lower in control and water treated TNF-α Ko mice compared to control
and water treated Wt mice. This finding showed that TNF-α Ko mice are less
protected against neuronal injury than Wt mice. The hippocampal IGF-I levels of KA
treated TNF-α mice were gradually decreased at all time points. On the other hand,
KA treated Wt mice showed a transient decrease in hippocampal levels of IGF-I
starting within 4 hr post KA treatment followed by returning back to normal levels 1
day post KA. Then the levels were significantly reduced at 3, 5, 15 and 30 days post
KA but not as much reduced as in TNF-α Ko mice.

It has been reported that in absence of TNFR1, most of the growth factors
were down-regulated. These included VEGF, EGF, IGF-I, and NGF, all of which
have been implicated in neuroprotection (Dirnagl et al., 2003). This finding
suggested that TNF-α can be pivotal for orchestrating the trophic microenvironment
of neuronal cells after injury.

TNF-α has a complex biological role in modulating immune and
inflammatory responses. Its functions are mediated through two receptors, TNFR1
and TNFR2. TNF binding with its receptors enables TNFR1-associated death domain
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protein (TRADD) to bind to the death domain. Following TRADD binding, NF-κB
pathway can be activated. NF-κB is a heterodimeric transcription factor that
translocates to the nucleus and mediates the transcription of a vast array of proteins
involved in cell survival and proliferation, inflammatory response, and anti-apoptotic
factors (Wajant et al., 2003). NF-κB is considered to be a point of convergence in the
signaling pathways activated by different survival factors, specially IGF-I (Balaram
et al., 1999; Vallee et al., 2003) and TNF-α (Jobin et al., 1999; Mukaida et al., 1990).
Activation of NF-κB promotes gene expression that can elicit either neurotoxic or
neuroprotective effects. Evidence for this dual role comes from studies that show that
TNF-α mediated induction of NF-κB is associated with neuronal survival (Albensi
and Mattson, 2000; Barger et al., 1995; Kaltschmidt et al., 1999) or the inability of
TNF-α to induce NF-κB is associated with increased neurotoxicity (Botchkina et al.,
1999; Sriram et al., 2006). Additionally, the stimulatory effect of TNF-α can be
mediated via the AKT signaling pathway. AKT is a serine/threonine protein kinase
that plays a key role in multiple cellular processes such as glucose metabolism, cell
proliferation, apoptosis, transcription and cell migration.

In this study, we examined NFκB and AKT expression one and five days
after KA treatment. Five days after KA treatment, TNF-α Ko mice showed
significantly higher NFκB expression than Wt mice, and there was no difference for
AKT expression among all groups of mice.

There is increasing evidence that intracellular ROS can function as second
messengers to regulate several downstream signaling molecules, including protein
kinase C, MAPK and NFκB (Guyton et al., 1996; Konishi et al., 1997; Schreck et al.,
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1991). Under physiological conditions this leads to a temporary activation of
signaling pathways. However, abnormally large concentrations of ROS/RNS may
lead to permanent changes in signal transduction and gene expression, typical for
disease states. NFκB, in particular, is often considered to be a ROS-responsive
transcription factor and is recognized as a major player in governing cellular
responses to oxidative stress (Janssen-Heininger et al., 2000). Importantly, NFκB is a
potent inducer of NADPH oxidase and iNOS and thus contributes to the generation
of ROS/RNS under proinflammatory conditions (Morgan and Liu, 2011). It is also
well established that NFκB can be activated by NADPH oxidase through ROS
intermediates (Brar et al., 2002; Clark and Valente, 2004; Gauss et al., 2007).

Studies using neuron-glia cultures from NADPH oxidase deficient mice have
shown that NADPH oxidase initiates an intracellular ROS signaling pathway
(Forman and Torres, 2002) that can activate microglia and amplify the production of
proinflammatory cytokines, such as TNF-α (Qin et al., 2004). In another study, Min
and colleagues (Min et al., 2004) demonstrated that the production of IL-1β, TNF-α
and iNOS are attenuated by the addition of the NADPH oxidase inhibitor,
diphenylene iodonium. Furthermore, inhibitors of NADPH oxidase are shown to
suppress LPS-induced expression of cytokines (IL-1β, IL-6, and TNF-α), iNOS,
MAPK, and NFκB phosphorylation (Pawate et al., 2004). Hence, there is a cross talk
between NADPH oxidase and NFκB, as both of them can regulate and alter the
expression of the other based on the surrounding environment. This interaction
between NFκB and NADPH oxidase demonstrates the strong interrelationship
between ROS/RNS production and the induction of proinflammatory cytokines,
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which results in enhanced cell damage and thus aggravates neurodegeneration
(Fischer and Maier, 2015).

A study conducted by Emmanouil and his colleagues showed that there is a
difference between the outcome of the induction of neuronal NFκB and glial NFκB,
where induction of NFκB in microglia, and to some extent in astrocytes, promotes
inflammation and neurodegeneration while induction of neuronal NFκB appears to
be neuroprotective (Emmanouil et al., 2009) as shown in Figure 37.

Figure 37: Role of NFκB in neuroprotective actions of TNF-α.
Signals that activate NFκB in microglia (e.g. ischemia, trauma, toxins) induce the
production and release of TNF-α. Then TNF-α/TNFR1 interaction on neurons and
astrocytes can lead to subsequent activation of NF-κB that promotes neuronal
survival by inducing the expression of genes encoding anti-apoptotic proteins (cIAP,
Bcl-2, Bcl-x), calcium-binding proteins (CBP), antioxidant enzymes (e.g. Mn-SOD)
and neurotrophic factors (NTF) (Figiel, 2008).

106
In our study, NFκB is upregulated in TNF-α Ko mice 5 days post KA
treatment. Of course, this upregulation is not mediated by TNF-α. Based on the
previous studies and the results of the current study, the possible mechanism for
NFκB upregulation may involve NADPH oxidase and the produced ROS. Moreover,
this upregulation of NFκB may be in microglia and astrocytes not in the neurons.
This may explain why the balance is going in the direction of inflammation and
neurodegeneration. In order to prove these postulations, further studies need to be
done. In absence of TNF-α, the neuroprotection mediated by TNF-α / NFκB axis is
lost and neurons become more vulnerable for degeneration by the surrounding
noxious molecules. We document that NFκB pathway, but not AKT, is important for
KA-induced neurotoxicity, which agrees with a previous report (Marchetti et al.,
2004) and that TNF-α may exert its neuroprotective role in KA induced neurotoxicity
via the regulation of NFκB activation.

Taking together all the results of the present study indicates a sequence of
events occurring in the process of KA-induced neurotoxicity within the duration of
the study. When KA is administered to the mice, it activates kainate receptors, which
are more abundant in the CA3 area of the hippocampus. Activation of KA receptors
produces membrane depolarization and results in alteration in intracellular calcium
concentrations, which is required to trigger the neuronal death cascade. KA
administration increases also the generation of ROS and reactive nitrogen species
(RNS) in the neurons. These events act as triggers to activate microglia (M1
phenotype) that respond by the release of inflammatory cytokines, ROS and NO.
Activated microglia stimulates proliferation

and activation of

astrocytes.

Excitotoxicity, neuroinflammation and oxidative stress contribute to neuronal cell
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death. Dead neurons represent a powerful trigger for further cycles of microglial
activation, astrogliosis and neurodegeneration.

TNF-α has been viewed as a neurotoxic agent that is over-expressed in
several cases of acute and chronic brain injury. Some studies encouraged therapeutic
approaches antagonizing or neutralizing TNF-α effect as a way to avoid its
neurotoxic potential. However, with the development of transgenic, knockdown and
knockout animals, some studies highlighted the neuroprotective effect of TNF-α by
using TNF-α receptors knockout mice. A recent study showed that mice lacking
TNFR1 exhibited greater hippocampal neurodegeneration, suggesting that TNFR1
may be protective in KA-induced neurotoxicity (Lu et al., 2008).

In this study, neurotoxicity was induced in TNF-α Ko mice and Wt mice by
intranasal administration of KA and the process was followed up at different time
points for 30 days. Absence of TNF-α resulted in rapid onset of seizures and severe
prolonged seizures. Significant behavioral changes, in the form of higher degree of
anxiety behavior, hyperactivity and defects in short-term memory, were observed in
TNF-α Ko mice. Severe neurodegeneration in both CA3 and CA1 areas of the
hippocampus associated with enhanced and prolonged microglial activation and
astrogliosis were shown in TNF-α Ko mice. Neuroinflammation, oxidative stress,
lack of antioxidant defensive mechanisms and lack of neuroprotective growth factors
were evident in TNF-α Ko mice compared to Wt mice.

From the results of this study we can suggest that: (1) Presence of TNF-α and
its early release after an excitotoxic insult is essential in priming microglial cells and
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innate immunity to effectively and specifically resolve and phagocytose the initial
excitotoxic damage, preventing subsequent secondary damage; (2) Absence of TNFα impairs microglial activation, which leads to an exaggerated and nonspecific
activation of microglia leading to exaggerated production of ROS and NO,
accumulation of necrotic debris, amplification of the secondary damage caused by
excitotoxin. It was found that the priming of microglial cells upon exposure to
neurotoxic insults is TNF-α specific (Blais and Rivest, 2004).

Collectively, the possible mechanisms by which TNF-α may mediate its
neuroprotective effects involve (1) regulation of ROS production, (2) activation of
astroglia and stimulating neurotrophic factor release (BDNF; Brain derived
neurotrophic factor) (Saha et al., 2006), (3) activation of repair processes, (4)
stimulation of synaptic currents and thereby mediating neuronal plasticity, (5)
activation of NFκ-B pathway, (6) induction of anti-apoptotic factors such as Bcl-2,
(7) induction of antioxidant defense pathways (GSH, Mn-SOD), (8) maintainance of
calcium homeostasis (Barger et al., 1995; Goodman and Mattson, 1996; Grassi et al.,
1994; Mattson et al., 1995; Sriram and O'Callaghan, 2007). TNF-α has been shown
to exert direct protective effects on neurons through both TNF receptors. TNFR1
signaling activates and sustains neuronal activity of the anti-apoptotic transcription
factor NFκB (Taoufik et al., 2007), and TNFR2 activates an Akt-dependent pathway
(Fontaine et al., 2002).

Our results add to the growing knowledge about the multiple factors involved
in the neurodegenerative process, specifically excitotoxicity, inflammation and
oxidative stress. They also support the growing evidence showing that TNF-α
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confers protection for the neurons, specifically for hippocampal neurons which are
the focus of our study. Highlighting the neuroprotective side of TNF-α provides an
important factor to be considered for future studies on therapeutic approaches
involving complete neutralization of TNF-α for treatment of various disorders. We
recommend that these treatments should be examined on different areas of the brain
to avoid the occurrence of side effects that would arise from complete deactivation of
the TNF signal-transduction cascade.
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Chapter 5: Final Conclusions
5.1

Summary
Neurodegeneration, which is the loss of nerve structure and/or function, is a

complicated process involving multiple components and interconnected mechanisms.
Excitotoxicity, neuroinflammation, mitochondrial dysfunction, oxidative stress and
protein aggregation seem to be the most common features shared between various
neurological diseases involving neurodegeneration (Przedborski et al., 2003).

Inflammation is a complex cascade of self-defensive response to noxious
stimuli. Acute inflammation is normally self-limiting and leads to the removal of
injurious stimuli and restoration of homeostasis. However, sustained inflammation
may result in cellular dysfunction and initiation of disease (Doty et al., 2015).

The resident innate immune cells in the CNS “microglia” provide the first
line of defense whenever injury or disease occurs. An acute insult to the CNS
(trauma, ischemia, infection, toxic insult) triggers rapid microglial activation with
subsequent changes in morphology, gene expression, number and function. Activated
microglia produce a spectrum of mediators, such as cytokines, chemokines, ROS,
NO and proteases (Prinz et al., 2014).

Of particular importance in neuroinflammatory events, the proinflammatory
cytokine, TNF-α, has been demonstrated to act as a key player in the initiation and
orchestration of inflammation with broadly ranging activities. TNF-α exerts both
homeostatic and pathophysiological roles in the CNS. From its initial description in
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peripheral inflammatory responses in 1975, TNF-α is unique in its ability to induce
selective necrosis of cancerous cells, while sparing normal counterparts (Carswell et
al., 1975). And till now a big controversy exists regarding the role of TNF-α in
neurodegeneration. TNF-α overexpression has been implicated in the pathogenesis of
several CNS injury including ischemia, trauma, infection, neurodegeneration, and
chemically induced neurotoxicity, and potentiates excitotoxic injury to human fetal
brain cells. On the other hand, several studies suggest neuroprotective properties for
TNF-α based on the findings that absence of TNF-α worsens CNS infections, and
knockout mice lacking both TNF receptors or TNFR1 receptors only show
exacerbated ischemic and excitotoxic brain damage. Furthermore, dysregulated TNFα signaling has been implicated in the initiation and/or progression of a number of
human diseases (Figiel, 2008; McCoy and Tansey, 2008; Probert, 2015; Sriram and
O'Callaghan, 2007). This conflict may be because TNF-α can activate both cell death
and survival pathways.

This study was conducted to investigate the role of TNF-α in
neurodegeneration and to follow up the sequence of events occurring in the
neurodegenerative process. This is achieved by induction of neurodegeneration via
excitotoxicity. Excitotoxic cell death is commonly induced experimentally by the
administration of kainic acid (KA) which is a non-degradable analog of glutamate
and 30-fold more neurotoxic than glutamate. It is a potent agonist affecting the
AMPA/kainate class of glutamate receptors. In our model, KA (40 mg/kg body
weight) was given intranasally under inhalational anesthesia to TNF-α Ko mice and
C57BL/6 Wt mice. The progress of the neurodegeneration at different time points
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(0.5 hr, 4 hr, 1, 3, 5, 15 and 30 days) was studied in order to have a better
understanding for the neurodegenerative process in presence and absence of TNF-α.

5.2

Conclusions
Intranasal administration of KA to both TNF-α Ko and Wt mice produced the

common characteristics of KA induced neurodegeneration in rodents. These include
development of recurrent seizures, behavioral changes, selective degeneration of
neuronal populations in the brain, oxidative stress, microglial activation and
astrogliosis with subsequent cytokines and other inflammatory molecules production
(Chen et al., 2002; Zheng et al., 2011).

The most important results and the major differences between TNF-α Ko and
Wt mice can be concluded in the following points:



TNF-α Ko mice were more susceptible to KA induced neurotoxicity as
demonstrated by rapid onset of seizures and long lasting severe seizures.



Both KA treated TNF-α Ko and Wt mice showed significantly changed behavior
in the form of altered risk assessment, decreased exploration, hyperactivity and
impaired short term memory.



TNF-α Ko mice changed behavior was significantly prominent specifically 3
days post KA when neuronal loss became evident.



Wt mice showed some sort of behavioral improvements in performance in EPM
and Y-maze at 30 days post KA, while TNF-α Ko mice did not. This may be due
to the severe neuronal loss and the continued gliosis observed in TNF-α Ko mice
at this time point.
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Hippocampal neurodegeneration was more severe and persisted longer in TNF-α
Ko mice.



Neurodegeneration was observed in both CA3 and CA1 areas in TNF-α Ko mice
while it was observed only in CA3 area in Wt mice.



Absence of TNF-α resulted in exaggerated non-specific activation of microglia.



Both microglial activation and astrogliosis were intense and extended in TNF-α
Ko mice and persisted up to 30 days post KA treatment.



Neuroinflammation occurred in both TNF-α Ko and Wt mice in the form of
increased levels of proinflammatory cytokines (IL-1β, IL-6 and IL-12) and
reduced levels of anti-inflammatory cytokines (IL-10).



Neuroinflammation was observed early in the course of the neurodegenerative
process even before neuronal death became detectable.



KA treated TNF-α Ko mice showed more severe and persistent oxidative stress
and increased NO production



GSH is the main antioxidant defensive mechanism stimulated in response to KA
induced oxidative stress in Wt mice. However, this mechanism is malfunctioning
in TNF-α Ko mice.



Absence of TNF-α resulted in increased vulnerability of the cells toward injury
by various mechanisms. This may be the reason behind the elevated basal levels
of GSH and CAT activity as compensatory mechanisms.



TNF-α Ko mice showed attempts to overcome the elevated oxidative stress
through CAT and SOD.



All the studied endogenous defensive mechanisms (GSH, CAT and SOD) were
observed in the early stages of the neurodegenerative process. However,
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continued oxidative stress resulted in failure of most of these mechanisms at late
time points especially in TNF-α Ko mice.


The basal levels of IGF-I in TNF-α Ko mice were lower than Wt mice. This may
indicate more vulnerability of TNF-α Ko mice to neuronal injury.



TNF-α Ko mice showed increased levels of β-NGF following KA treatment, may
be as a defensive mechanism to prevent severe damage.



KA treatment significantly upregulated the expression of NFκB 5 days post KA
in TNF-α Ko mice.



Activation and upregulation of NFκB may be due to the uncontrolled oxidative
stress and NADPH oxidase mediated ROS production in TNF-α Ko mice.

In summary, deficiency of TNF-α worsens KA induced neurotoxicity. The
neuroprotective effects of TNF-α may be mediated through the regulation of
microglial activation, induction of antioxidant defensive mechanisms and regulation
of the NFκB signaling pathway.
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Chapter 6: Limitations and Future Directions
6.1

Limitations of the Study
There were some limitations in this study including the use of one animal

model for induction of neurodegeneration. We preferred to use adult male mice as
female and aged C57BL/6 mice were found to be more sensitive to KA-induced
neurodegeneration (Zhang et al., 2008), but it will be good if other studies include
female subjects as well. Another limitation is the lack of the proper markers to
identify M1 and M2 microglia. It is important to appreciate that the use of knockout
and transgenic animals helps in understanding the gene function; however there is
limited knowledge about the compensatory mechanisms associated with genetically
modified animals. Based on the pleotropic effects of TNF-α, there may be some
‘unknown’ compensatory mechanisms occurring in these mice. So it is better to use
animal models with specific inhibition of TNF-α signaling without interference with
genetics.

6.2

Recommendations for Future Work
In this study, we were able to demonstrate the neuroprotective effects of

TNF-α in KA induced neurotoxicity. Our findings added more to the growing
evidence showing that TNF-α confers protection to neurons. However, we cannot
generalize these findings to all cases of neurodegeneration and say that the definite
role of TNF-α in all neurodegeneration is neuroprotection. Still the precise role of
TNF-α in neurodegeneration remains highly controversial due to the complexity and
pleiotropic nature of this cytokine and the activities attributed to TNF-α during
critical developmental and homeostatic cellular processes. Multiple factors determine
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whether TNF-α will exert deleterious or beneficial effects for neuronal survival.
These factors may include its concentration, duration of expression (transient or
chronic), receptor conformation, tissue type, cellular context and the inflammatory
milieu. Because of this multiple variables, caution is necessary when clinically
inhibiting the activity of TNF-α, as it is likely that prolonged global suppression of
TNF-α and/or TNF-receptor signaling may not be an effective approach to modify
the course of neurodegeneration and may even intensify the disease state.

In this study, KA was used to induce hippocampal neurodegeneration,
whereas, for future studies, it is important to utilize other models for induction of
neurodegeneration to study the neuroprotective role of TNF-α. Furthermore, since we
used TNF-α Ko mice as an animal model for deficiency of TNF-α, additional studies
involving different ways for TNF-α/TNF-α receptors inhibition, without interference
with genetics, will be useful. It is of paramount importance to conduct more research
to uncover the possible mechanisms underlying the neuroprotective effects of TNFα. The NFB signaling pathway may represent a promising target to be extensively
studied at different time points to clarify more the TNF-α neuroprotective effects.
Microglial NADPH oxidase and its cross talk with NFκB may represent another
promising target to be studied. Future studies focusing on microglial activation
phenotypes (M1 and M2) with subsequent morphological changes should be carried
out in presence and absence of TNF-α. Finally, further in vivo dissection of TNF-α
signaling and its associated receptors in a cell and stage specific context is required
for the successful development of selective therapeutic interventions that are safe,
specific and efficiently enhance the neuroprotective actions and ameliorate the
deleterious actions of TNF-α in neurodegenerative diseases.
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